Autonomous bioluminescence reporter, variants thereof, and methods of making and using

A compact single-transcript bioluminescence reporter system with optimized genes and GC content addresses the issues of FBP3's complexity, achieving up to 16-fold enhanced bioluminescence in organisms.

WO2026235839A2PCT designated stage Publication Date: 2026-11-12RGT UNIV OF CALIFORNIA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/021480
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-04-03
Filing Date
2026-03-30
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing bioluminescence pathways, such as FBP3, are large and cumbersome, containing multiple genes and splice sites that interfere with protein expression, leading to silencing and low expression, and there is a need for improved bioluminescent pathways with increased luminescence intensity.

Method used

A compact single-transcript bioluminescence reporter system is developed using a bacterial operon-like design with 2A self-cleaving peptides, codon optimization, removal of intron sites, and optimized GC content, linking genes like HispS, H3H, CPH, and npgA to enhance bioluminescence.

Benefits of technology

The solution results in a bioluminescent organism with enhanced bioluminescence intensity, up to 16-folds higher, and improved protein expression stability, suitable for various organisms including plants and animals.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026021480_12112026_PF_FP_ABST
    Figure US2026021480_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Autonomous bioluminescence reporters comprising coding sequences sufficient to confer superior bioluminescence to cells, an organism, or selected portions of an organism, and methods of making and using the constructs are described.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Attorney Docket No.: 690104.0045

[0002] AUTONOMOUS BIOLUMINESCENCE REPORTER, VARIANTS THEREOF, AND METHODS OF MAKING AND USING

[0003] Cross-Reference to Related Applications;

[0004] This application claims priority under 35 U. S. C. § 119(e) to US Provisional Application No. 63 / 782,980, filed April 3, 2025, the disclosure of which is incorporated by reference in its entirety.

[0005] Government License Right:

[0006] This invention was made with government support under Grant Number: D24AC00011-00 awarded by the Defense Research Projects Agency CERES. The government has certain rights in the invention.

[0007] Reference to Sequence Listing Submitted Electronically;

[0008] The Sequence Listing associated with this application is provided in XML format, and is hereby incorporated by reference into the specification. The name of the XML file containing the Sequence Listing is “690104.0045 Sequence Listing.” The XML file is 543.6 kilobytes, was created on March 23, 2026, and is being submitted electronically, concurrent with the filing of this application.

[0009] Field of Invention:

[0010] The invention pertains to the field of biochemical and molecular biology, specifically in the area of bioluminescence. It focuses on the novel creation and characterization of an autonomous bioluminescence reporter comprising coding sequences sufficient to confer superior bioluminescence to cells, an organism, or selected portions of an organism within a single transcript construct. This discovery has potential applications in bioengineering and agricultural biotechnology.

[0011] Attorney Docket No.: 690104.0045

[0012] Background of the Invention:

[0013] The fungal bioluminescence pathway, first described in 2018, has been optimized through multiple rounds to produce FBP3 (Fungal Bioluminescence Pathway version 3), which enables bright auto luminescence in plants. Despite the impressive advance, the FBP3 construct (Figure 1) is large and cumbersome, consisting of five genes spanning 15.3 kb, with multiple repeated sequences. Its components also contain many predicted splice site acceptors and donors, which may interfere with protein expression levels in plant cells. These complexities make the FBP3 and related constructs challenging to work with and prone to silencing and low expression.

[0014] Additionally, increased intensity of luminescence resulting from bioluminescent pathways could be desired in certain circumstances. It is possible that intensity of luminescence could be increased by altering the nucleotide and / or amino acid sequences of the genes / proteins in the FBP3 pathway.

[0015] There remains a need in the art for improved bioluminescent pathways and transgenic organisms exhibiting bioluminescence through such pathways.

[0016] Summary of the Invention:

[0017] Autonomous bioluminescence reporters are described, comprising coding sequences sufficient to confer superior bioluminescence to cells, an organism, or selected portions of an organism. Methods of making and using the constructs are also described.

[0018] In particular embodiments, we created a more compact reporter system by designing a single-transcript version of the FBP3 pathway that can be expressed using a single promoter and terminator (e.g., the five FBP3 enzymes were linked by 2A self-cleaving peptides, allowing the transcript to mimic a bacterial operon). (Figure 2). In other embodiments, we created variant versions of the genes of the pathway through a sequence design process that involved one or more of (1) codon optimization, (2) systematic computational identification and removal of predicted intron donor and acceptor sites, and (3) optimization of GC content. In further embodiments, we created mutant proteins of the genes within the pathway.

[0019] In certain embodiments, the present application describes a bioluminescent organism comprising a bioluminescent transgene cassette. In certain examples the bioluminescent organism expresses a plurality of heterologous genes of a bioluminescence pathway. In certain examples, two or more of the genes of a bioluminescence pathway are included in a

[0020] Attorney Docket No.: 690104.0045

[0021] bioluminescent transgene cassette. In other examples, the genes in the bioluminescent transgene cassette are transcribed as a single transcript and the single transcript is translated into a separate protein for each gene within the cassette.

[0022] In embodiments, one or more of the genes of the bioluminescent pathway are linked to each other by one or more LP4 / 2A ribosomal skipping peptides. In embodiments, one or more of the genes of the bioluminescent pathway are codon-optimized. In embodiments, one or more of the genes of the bioluminescent pathway lack predicted intron donor sites and predicted intron acceptor sites. In embodiments, one or more of the genes of the bioluminescent pathway have a GC content between 50% and 70%. In embodiments, one or more of the genes of the bioluminescent pathway are transcribed into a single 9.5 kb transcript.

[0023] In embodiments, one or more of the genes of the bioluminescent pathway comprise HispS, H3H, CPH, and npgA. In embodiments, the single transcript comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, and SEQ ID NO: 236. In embodiments, the single transcript encodes a variant protein comprising an amino acid sequence of any one of SEQ ID NOs: 247-278.

[0024] In embodiments, the variant protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 263, SEQ ID NO: 266, SEQ ID NO: 269, SEQ ID NO: 275, and SEQ ID NO: 276. In embodiments, the variant protein comprises the mutations A43T, T66I, S102P, and D263A relative to an H3H polypeptide of SEQ ID NO: 239. In embodiments, the variant protein increases the bioluminescence of the bioluminescent organism by at least 16-folds. In embodiments, the bioluminescent organism expresses a variant protein comprising SEQ ID NO: 269.

[0025] In embodiments, the bioluminescent organism is an animal. In embodiments, the animal is a fish, an arthropod, or a mammal.

[0026] In embodiments, the bioluminescent organism is a plant. In embodiments, the plant is an ornamental plant. In embodiments, the ornamental plant is a petunia, impatiens, rose, begonia, geranium, or the like.

[0027] In other embodiments, the present application describes a bioluminescent transgene cassette comprising two or more genes of a bioluminescence pathway where the genes in the bioluminescent transgene cassette are transcribed as a single transcript, and the single transcript is translated into a separate protein for each gene within the cassette.

[0028] Attorney Docket No.: 690104.0045

[0029] In further examples the genes of the bioluminescence pathway comprise HispS, H3H, LUZ, CPH, and npgA; the bioluminescent transgene cassette comprises three or more, preferably four or more, and most preferably all five of the genes of the bioluminescence pathway; two, three, or four of the bioluminescence pathway genes are on the bioluminescent transgene cassette and the remaining bioluminescence pathway genes are external to the cassette, optionally wherein two or three of the remaining bioluminescence pathway genes are part of a second bioluminescent transgene cassette that are transcribed as a single transcript; the genes in the bioluminescent transgene cassette are separated from one another by one or more linkers that are self-cleaving linkers or protein cleavage sites, optionally wherein the linker comprises LP4, 2A, GSG, or combinations thereof, optionally wherein the linker comprises one or more of SEQ ID NOs: 78-79, 81-82, 84-85, 87-88, 91-92, 94-95, 97-98, 100-101, 104-105, 107-108, 110-111, 113-114, 117-118, 120-121, 123-124, 126-127, 130-131, 133-134, 136-137, 139-140, 143-144, 146-147, 149-150, 152-153, 156-157, 159-160, 162-163, 165-166, 169-170, 172-173, 175-176, 178-179, 182-183, 185-186, 188-189, 191-192, 195-196, 198-199, 201-202, 204-205, 208-209, 211-212, 214-215, 217-218, 221-222, 224-225, 227-228, and 230-231; the bioluminescent transgene cassette comprises a nucleotide sequence selected from SEQ ID NOs: 1-12 or 233-236; the bioluminescent organism is a plant or animal; one or more of the genes of the bioluminescent pathway have been modified from the wild type by one or more of: removal of intron splice sites, codon optimization, and altering GC content, optionally wherein GC content is increased to 50% or more, 52% or more, 54% or more, 56% or more, 58% or more, or 60% or more; one or more of the genes of the bioluminescence pathway comprise a nucleotide sequence selected from the group consisting of SEQ ID NOs: 77, 80, 83, 86, 89-90, 93, 96, 99, 102-103, 106, 109, 112, 115-116, 119, 122, 125, 128-129, 132, 135, 138, 141-142, 145, 148, 151, 154-155, 158, 161, 164, 167-168, 171, 174, 177, 180-181, 184, 187, 190, 193-194, 197, 200, 203, 206-207, 210, 213, 216, 219-220, 223, 226, 229, and 242-246; one or more of the genes of the bioluminescence pathway comprise a variant gene of HispS, H3H, LUZ, CPH, and npgA such that the nucleotide sequence, when translated, produces a variant protein with an amino acid sequence that differs from the wildtype amino acid sequence; and / or the variant gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 13-76; and / or the variant protein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 247-278.

[0030] Attorney Docket No.: 690104.0045

[0031] In further embodiments, the present application describes a method of producing a bioluminescent organism comprising transforming a cell with the bioluminescent transgene cassette, wherein the bioluminescent organism is a plant or animal.

[0032] In other embodiments, the present application describes a variant bioluminescence pathway protein. In certain examples the variant bioluminescence pathway protein comprises an amino acid sequence of any one of SEQ ID NOs: 247-278.

[0033] In yet other embodiments, the present application describes mutant H3H polypeptides exhibiting enhanced bioluminescence activity.

[0034] In further embodiments, the present application describes a variant bioluminescence pathway gene. In certain examples the variant bioluminescence pathway gene comprises nucleotide sequence of any one of SEQ ID NOs: 77, 80, 83, 86, 89-90, 93, 96, 99, 102-103, 106, 109, 112, 115-116, 119, 122, 125, 128-129, 132, 135, 138, 141-142, 145, 148, 151, 154-155, 158, 161, 164, 167-168, 171, 174, 177, 180-181, 184, 187, 190, 193-194, 197, 200, 203, 206-207, 210, 213, 216, 219-220, 223, 226, 229, 242-246, and 13-76.

[0035]

[0036] FIG. 1: An illustration of a fungal bioluminescence construct.

[0037] FIG. 2: An example of a single transcript STARBURST construct compactly providing coding sequences to confer bioluminescence in a plant.

[0038] FIG.3: A comparison of predicted intron donor and acceptor sites between FBP3 gene sequences and “deintronized” STARBURST construct.

[0039] FIG. 4: A comparison between transgenic expression of FBP in Firefly Petunia and STARBURST transiently expressed in Nicotiana benthamiana.

[0040] FIG. 5: Table demonstrating genes codon optimized by matching codon usage have higher variability in their GC content relative to those optimized with GC boosting using the method described herein. To generate the table, GC content was first calculated in 60-base sliding windows for each gene, yielding a set of raw GC values across its length. The mean (GC %), median (GC %), sd (%), and Coefficient of Variance (CoV) (sd / mean) are displayed in the table.

[0041] FIG. 6: Genes codon optimized by matching codon usage have higher variability in GC content relative to those optimizied with GC boosting as described above. To generate thisAttorney Docket No.: 690104.0045

[0042] figure, GC content was first calculated in 60-base sliding windows for each gene, yielding a set of raw GC values across its length. Next, a moving-average smoothing (window of 5) was applied to these values, replacing each point with the average of its neighbors to emphasize broader trends and reduce local noise. Each gene’s smoothed values were then normalized by dividing by that gene’s mean GC content, allowing direct comparisons across genes despite differences in baseline GC levels. Genes optimzied with match codon usage (annotated with mcu) have much greater variability in GC content across their lengths than those with GC boosting, as indicated by the great spread around the normalized mean.

[0043] FIG. 7: A schematic of gene assembly from oligonucleotide pool templates using the experimental gene-synthesis pipeline, iggypop.

[0044] FIG. 8A: A simplified schematic of iggypop assembly.

[0045] FIG. 8B: An analysis summarizing assembly success rates, and assembly outcome for 52 transcription factor constructs assembled using iggypop

[0046] FIG. 8C: Schematic representation of iggypop assembly for three ~3 kb sequences, each containing a GFP expression cassette.

[0047] FIG. 9A: A schematic of a Two-step iggypop gene assembly strategy.

[0048] FIG. 9B: A depiction of the STARBURST constructs (clones 1-5), which link the five genes of the fungal bioluminescence pathway in three different gene orders with LP4 / 2A ribosomal skipping peptides.

[0049] FIG. 9C: A depiction of previously published expression cassette for an optimized N. nambi pathway, which was used as an N. nambi control.

[0050] FIG. 9D: Image of bioluminescence of transgenic N. benthamiana leaves expressing clones 1-5 and the A. nambi control.

[0051] FIG. 9E: Image of bioluminescence transgenic A benthamiana leaf expressing 35S-clone #3.

[0052] FIG. 10: Image of final T-DNA yielded from 35S-driven STARBURST (corresponding to clone #3) and image of bioluminescence in planta expressing 35S-STARBURST clone #3.

[0053] FIG. 11A: Analysis of transient expression of six Arabidopsis-codon-matched variants with low GC content and RUBY in A. benthamiana.

[0054] FIG. 11B: Quantification of pigmentation levels of transient expression of six dra / i / r / ryzs / .s-codon- atched variants with low GC content and RUBY in A. benthamiana.

[0055] Attorney Docket No.: 690104.0045

[0056] FTG. 11C: An image of the luminescence in N. benthamiana produced by six GC-boosted STARBURSTs compared to a STARBURST (design #2 gene order HispS; npgA;

[0057] H3Hv2; LUZv4; CPH) with only 48% GC content

[0058] FIG. 11D: Comparison of the luminescence between produced by six GC -boosted STARBURSTs and a STARBURST (design #2 gene order HispS; npgA; H3Hv2; LUZv4;

[0059] CPH)with only 48% GC content expressed in N. benthamiana. Three leaf punches per spot (n = 7 or greater leaves) were collected, and luminescence was measured using a Tecan Spark spectrophotometer.

[0060] FIG. 12A: Distribution of codon adaptation index values, GC content, and synonymous 3rd position GC usage (GC3s) for all Arabidopsis coding sequences (violin plots) with overlays of the RUBY sequence (red dot), a concatenated sequence of the three B. vulgaris genes comprising RUBY (blue dot) and the designed Arabidopsis codon-matched RUBY derivatives from Figure 9B.

[0061] FIG. 12B: GC, GC3s, and CAI values for RUBY and other genes. The CAI values shown were calculated using Arabidopsis, Nicotiana, and Orzya codon tables obtained from the CoCoPUTs database (31).

[0062] FIG. 13: Luminescence observed in planta from high GC content STARBURST.

[0063] FIG. 14: Comparison of the luminescence for transient expression of Luciferase mutant clones (Nucleotide sequences: SEQ ID NOS: 13-28; Amino acid sequences: SEQ ID NOS: 247-262 and the control NnLuzv4 (Nucleotide sequence: SEQ ID NO: 245; amino acid sequence: SEQ ID NO: 240) in N. benthamiana leaves co-infdtrated with STARBURST (clone #3) (SEQ ID NO: 233) with nnLUZv4 gene removed and pl9.

[0064] FIG. 15: Comparison of the luminescence for transient expression of nnH3Hv2 mutant clones (Nucleotide sequences: SEQ ID NOS: 45-60; Amino acid sequences: SEQ ID NOS: 263-278) or the control nnH3Hv2 (Nucleotide sequence: SEQ ID NO: 244; and amino acid sequence: SEQ ID NO: 239) in N. benthamiana leaves co-infiltrated with STARBURST (clone #3) (SEQ ID NO: 234) with nnH3Hv2 gene removed and pl9.

[0065] FIG. 16: The overhang set sizes, the number of fragments required for assembly from 250 bp oligos, predicted ligation fidelities for the set, and summary statistics are displayed for a collection of ~10K transcription factor coding sequences for citrus, hemp, beet, and papaya was collated from TfDB (51).

[0066] Attorney Docket No.: 690104.0045

[0067] uence information:

[0068] SEQ ID NO. 1: Nucleotide sequence of STARBURST (clone #1 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH) - FB3_2Aified_di_mcu-l clone #1

[0069] SEQ ID NO. 2: Nucleotide sequence of STARBURST (clone #2 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH) -FB3_2Aified_di_mcu-2 clone #2

[0070] SEQ ID NO. 3: Nucleotide sequence of STARBURST (clone #3 - gene order: HispS; npgA;

[0071] H3Hv2; LUZv4; CPH) - FBP3-2A v2 di mcu-2 clone #3

[0072] SEQ ID NO. 4: Nucleotide sequence of STARBURST (clone #4 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH) - FBP3-2A_v2_di_mcu-3 clone #4

[0073] SEQ ID NO. 5: Nucleotide sequence of STARBURST (clone #5 - gene order: UUZv4; HispS; npgA; H3Hv2; CPH) - FBP3_2A_v3_di_mcu-l clone #5

[0074] SEQ ID NO. 6: Nucleotide sequence of STARBURST (design #2 gene order: HispS; npgA;

[0075] H3Hv2; LUZv4; CPH) with 48% GC content. - STARBURST_gen_48_gc_gc3s_38

[0076] SEQ ID NO. 7: Nucleotide sequence of STARBURST (design #2 gene order: HispS; npgA;

[0077] H3Hv2; LUZv4; CPH) with 53% GC content. - STARBURST_53gc_gc3s_50

[0078] SEQ ID NO. 8: Nucleotide sequence of STARBURST (design #2 gene order: HispS; npgA;

[0079] H3Hv2; LUZv4; CPH) with 55% GC content. - STARBURST_55gc_gc3s_55

[0080] SEQ ID NO. 9: Nucleotide sequence of STARBURST (design #2 gene order: HispS; npgA;

[0081] H3Hv2; LUZv4; CPH) with 57% GC content. - STARBURST_57gc_gc3s_61

[0082] SEQ ID NO. 10: Nucleotide sequence of STARBURST (design #2 gene order: HispS; npgA;

[0083] H3Hv2; LUZv4; CPH) with 59% GC content. - STARBURST_59gc_gc3s_66

[0084] SEQ ID NO. 11: Nucleotide sequence of STARBURST (design #2 gene order: HispS; npgA;

[0085] H3Hv2; LUZv4; CPH) with 60% GC content. - STARBURST_60gc_gc3s_70

[0086] SEQ ID NO. 12: Nucleotide sequence of STARBURST (design #2 gene order: HispS; npgA;

[0087] H3Hv2; LUZv4; CPH) with 62% GC content. - STARBURST_62gc_gc3s_75

[0088] SEQ ID NO. 13: Nucleotide sequence of nnUUZv4 mutant 1 with standard Arabidopsis codon usage (nnLUZv4 mutant 1). STARBURST_nnLUZ_mut_1.1 l_B10_set23

[0089] SEQ ID NO. 14: Nucleotide sequence of nnUUZv4 mutant 2 with standard Arabidopsis codon usage (nnUUZv4 mutant 2). STARBURST_nnLUZ_mut_2.1 l_Bll_set24

[0090] SEQ ID NO. 15: Nucleotide sequence of nnLUZv4 mutant 3 with standard Arabidopsis codon usage (nnLUZv4 mutant 3). STARBURST_nnLUZ_mut_3.1 l_B12_set25

[0091] SEQ ID NO. 16: Nucleotide sequence of nnUUZv4 mutant 4 with standard Arabidopsis codon usage (nnLUZv4 mutant 4). STARBURST_nnLUZ_mut_4.1 l_C01_set26

[0092] Attorney Docket No.: 690104.0045

[0093] SEQ ID NO. 17: Nucleotide sequence of nnLUZv4 mutant 5 with standard Arabidopsis codon usage (nnLUZv4 mutant 5). STARBURST nnLUZ mut 5.1 1 C02 set27

[0094] SEQ ID NO. 18: Nucleotide sequence of nnLUZv4 mutant 6 with standard Arabidopsis codon usage (nnLUZv4 mutant 6). STARS URST_nnLUZ_mut_6.1 l_C03_set28

[0095] SEQ ID NO. 19: Nucleotide sequence of nnLUZv4 mutant 7 with standard Arabidopsis codon usage (nnLUZv4 mutant 7). STARS URST_nnLUZ_mut_7.1 l_C04_set29

[0096] SEQ ID NO. 20: Nucleotide sequence of nnLUZv4 mutant 8 with standard Arabidopsis codon usage (nnLUZv4 mutant 8). STARS URST_nnLUZ_mut_8.1 l_C05_set30

[0097] SEQ ID NO. 21: Nucleotide sequence of nnLUZv4 mutant 9 with standard Arabidopsis codon usage (nnLUZv4 mutant 9). STARS URST_nnLUZ_mut_9.1 l_C06_set31

[0098] SEQ ID NO. 22: Nucleotide sequence of nnLUZv4 mutant 10 with standard Arabidopsis codon usage (nnLUZv4 mutant 10). STARS URST nnLUZ mut l 0.1 l_C07_set32

[0099] SEQ ID NO. 23: Nucleotide sequence of nnLUZv4 mutant 11 with standard Arabidopsis codon usage (nnLUZv4 mutant 11). STARS URST nnLUZ mut l 1.1 l_C08_set33

[0100] SEQ ID NO. 24: Nucleotide sequence of nnLUZv4 mutant 12 with standard Arabidopsis codon usage (nnLUZv4 mutant 12). STARS URST nnLUZ mut l 2.1 l_C09_set34

[0101] SEQ ID NO. 25: Nucleotide sequence of nnLUZv4 mutant 13 with standard Arabidopsis codon usage (nnLUZv4 mutant 13). STARS URST nnLUZ mut l 3.1 l_C10_set35

[0102] SEQ ID NO. 26: Nucleotide sequence of nnLUZv4 mutant 14 with standard Arabidopsis codon usage (nnLUZv4 mutant 14). STARS URST_nnLUZ_mut_14.1 l_Cll_set36

[0103] SEQ ID NO. 27: Nucleotide sequence of nnLUZv4 mutant 15 with standard Arabidopsis codon usage (nnLUZv4 mutant 15). STARS URST nnLUZ mut l 5.1 l_C12_set37

[0104] SEQ ID NO. 28: Nucleotide sequence of nnLUZv4 mutant 16 with standard Arabidopsis codon usage (nnLUZv4 mutant 16). STARS URST nnLUZ mut l 6.1 l_D01_setl23

[0105] SEQ ID NO. 29: Nucleotide sequence of GC-boosted nnLUZv4 mutant 1 from SEQ ID NO. 13 (nnLUZv4 mutant 1 GC-boosted). STARS URST nnLUZ mut l.l gc boosted

[0106] SEQ ID NO. 30: Nucleotide sequence of GC-boosted nnLUZv4 mutant 2 from SEQ ID NO. 14 (nnLUZv4 mutant 2 GC-boosted). STARS URST_nnLUZ_mut_2.1_gc_boosted

[0107] SEQ ID NO. 31: Nucleotide sequence of GC-boosted nnLUZv4 mutant 3 from SEQ ID NO. 15 (nnLUZv4 mutant 3 GC-boosted). STARS URST_nnLUZ_mut_3.1_gc_boosted

[0108] SEQ ID NO. 32: Nucleotide sequence of GC-boosted nnLUZv4 mutant 4 from SEQ ID NO. 16 (nnLUZv4 mutant 4 GC-boosted). STARS URST_nnLUZ_mut_4.1_gc_boosted

[0109] SEQ ID NO. 33: Nucleotide sequence of GC-boosted nnLUZv4 mutant 5 from SEQ ID NO. 17 (nnLUZv4 mutant 5 GC-boosted). STARS URST_nnLUZ_mut_5.1_gc_boosted

[0110] Attorney Docket No.: 690104.0045

[0111] SEQ ID NO. 34: Nucleotide sequence of GC-boosted nnLUZv4 mutant 6 from SEQ ID NO. 18 (nnLUZv4 mutant 6 GC-boosted). STARBURST nnLUZ mut 6.1 gc boosted

[0112] SEQ ID NO. 35: Nucleotide sequence of GC-boosted nnLUZv4 mutant 7 from SEQ ID NO. 19

[0113] (nnLUZv4 mutant 7 GC-boosted). STARBURST_nnLUZ_mut_7.1_gc_boosted

[0114] SEQ ID NO. 36: Nucleotide sequence of GC-boosted nnLUZv4 mutant 8 from SEQ ID NO. 20 (nnLUZv4 mutant 8 GC-boosted). STARBURST_nnLUZ_mut_8.1_gc_boosted

[0115] SEQ ID NO. 37: Nucleotide sequence of GC-boosted nnLUZv4 mutant 9 from SEQ ID NO. 21 (nnLUZv4 mutant 9 GC-boosted). STARBURST_nnLUZ_mut_9.1_gc_boosted

[0116] SEQ ID NO. 38: Nucleotide sequence of GC-boosted nnLUZv4 mutant 10 from SEQ ID NO. 22 (nnLUZv4 mutant 10 GC-boosted). STARBURST_nnLUZ_mut_10.1_gc_boosted

[0117] SEQ ID NO. 39: Nucleotide sequence of GC-boosted nnLUZv4 mutant 11 from SEQ ID NO. 23 (nnLUZv4 mutant 11 GC-boosted). STARBURST nnLUZ mut ll.l gc boosted

[0118] SEQ ID NO. 40: Nucleotide sequence of GC-boosted nnLUZv4 mutant 12 from SEQ ID NO. 24 (nnLUZv4 mutant 12 GC-boosted). STARBURST_nnLUZ_mut_12.1_gc_boosted

[0119] SEQ ID NO. 41: Nucleotide sequence of GC-boosted nnLUZv4 mutant 13 from SEQ ID NO. 25 (nnLUZv4 mutant 13 GC-boosted). STARBURST_nnLUZ_mut_13.1_gc_boosted

[0120] SEQ ID NO. 42: Nucleotide sequence of GC-boosted nnLUZv4 mutant 14 from SEQ ID NO. 26 (nnLUZv4 mutant 14 GC-boosted). STARBURST_nnLUZ_mut_14.1_gc_boosted

[0121] SEQ ID NO. 43: Nucleotide sequence of GC-boosted nnLUZv4 mutant 15 from SEQ ID NO. 27 (nnLUZv4 mutant 15 GC-boosted). STARBURST_nnLUZ_mut_15.1_gc_boosted

[0122] SEQ ID NO. 44: Nucleotide sequence of a GC-boosted nnLUZv4 mutant 16 from SEQ ID NO: 28 (nnLUZv4 mutant 16 GC-boosted). STARBURST_nnLUZ_mut_16.1_gc_boosted

[0123] SEQ ID NO. 45: Nucleotide sequence of nnH3Hv2 mutant 1 with standard Arabidopsis codon usage (nnH3Hv2 mutant 1). H3H_mutant_vl.l l_A05_set5

[0124] SEQ ID NO. 46: Nucleotide sequence of nnH3Hv2 mutant 2 with standard Arabidopsis codon usage. H3H_mutant_v2.1 l_A06_set6

[0125] SEQ ID NO. 47: Nucleotide sequence of nnH3Hv2 mutant 3 with standard Arabidopsis codon usage. H3H_mutant_v3.1 l_A07_set8

[0126] SEQ ID NO. 48: Nucleotide sequence of nnH3Hv2 mutant 4 with standard Arabidopsis codon usage. H3H_mutant_v4.1 l_A08_set9

[0127] SEQ ID NO. 49: Nucleotide sequence of nnH3Hv2 mutant 5 with standard Arabidopsis codon usage. H3H_mutant_v5.1 l_A09_setl0

[0128] SEQ ID NO. 50: Nucleotide sequence of nnH3Hv2 mutant 6 with standard Arabidopsis codon usage. H3H_mutant_v6.1 l_A10_setll

[0129] Attorney Docket No.: 690104.0045

[0130] SEQ ID NO. 51: Nucleotide sequence of nnH3Hv2 mutant 7 with standard Arabidopsis codon usage. H3H mutant v7.1 1 All setl2

[0131] SEQ ID NO. 52: Nucleotide sequence of nnH3Hv2 mutant 8 with standard Arabidopsis codon usage. H3H_mutant_v8.1 l_A12_setl3

[0132] SEQ ID NO. 53: Nucleotide sequence of nnH3Hv2 mutant 9 with standard Arabidopsis codon usage. H3H_mutant_v9.1 l_B01_setl4

[0133] SEQ ID NO. 54: Nucleotide sequence of nnH3Hv2 mutant 10 with standard Arabidopsis codon usage. H3H_mutant_vl0.1 l_B02_setl5

[0134] SEQ ID NO. 55: Nucleotide sequence of nnH3Hv2 mutant 11 with standard Arabidopsis codon usage. H3H_mutant_vll.l l_B03_setl6

[0135] SEQ ID NO. 56: Nucleotide sequence of nnH3Hv2 mutant 12 with standard Arabidopsis codon usage. H3H_mutant_vl2.1 l_B04_setl7

[0136] SEQ ID NO. 57: Nucleotide sequence of nnH3Hv2 mutant 13 with standard Arabidopsis codon usage. H3H_mutant_v 13.1 l_B05_setl 8

[0137] SEQ ID NO. 58: Nucleotide sequence of nnH3Hv2 mutant 14 with standard Arabidopsis codon usage. H3H_mutant_vl4.1 l_B06_setl9

[0138] SEQ ID NO. 59: Nucleotide sequence of nnH3Hv2 mutant 15 with standard Arabidopsis codon usage. H3H_mutant_vl5.1 l_B07_set20

[0139] SEQ ID NO. 60: Nucleotide sequence of nnH3Hv2 mutant 16 with standard Arabidopsis codon usage. H3H_mutant_vl6.1 l_B08_set21

[0140] SEQ ID NO. 61: Nucleotide sequence of GC -boosted nnH3Hv2 mutant 1 from SEQ ID NO. 45. H3H_mutant_vl. I gc boosted

[0141] SEQ ID NO. 62: Nucleotide sequence of GC -boosted nnH3Hv2 mutant 2 gene from SEQ ID

[0142] NO. 46. H3H_mutant_v2.1_gc_boosted

[0143] SEQ ID NO. 63: Nucleotide sequence of GC-boosted nnH3Hv2 mutant 3 from SEQ ID NO. 47. H3H_mutant_v3. I gc boosted

[0144] SEQ ID NO. 64: Nucleotide sequence of GC-boosted nnH3Hv2 mutant 4 from SEQ ID NO. 48. H3H_mutant_v4. l_gc_boosted

[0145] SEQ ID NO. 65: Nucleotide sequence of GC-boosted nnH3Hv2 mutant 5 from SEQ ID NO. 49. H3H_mutant_v5. I gc boosted

[0146] SEQ ID NO. 66: Nucleotide sequence of GC-boosted nnH3Hv2 mutant 6 from SEQ ID NO. 50. H3H_mutant_v6. I gc boosted

[0147] SEQ ID NO. 67: Nucleotide sequence of GC-boosted nnH3Hv2 mutant 7 from SEQ ID NO. 51.

[0148] H3H_mutant_v7. l_gc_boosted

[0149] Attorney Docket No.: 690104.0045

[0150] SEQ ID NO. 68: Nucleotide sequence of GC-boosted nnH3Hv2 mutant 8 from SEQ ID NO. 52.

[0151] H3H mutant v8.1 gc boosted

[0152] SEQ ID NO. 69: Nucleotide sequence of GC-boosted nnH3Hv2 mutant 9 from SEQ ID NO. 53. H3H_mutant_v9. I gc boosted

[0153] SEQ ID NO. 70: Nucleotide sequence of GC-boosted nnH3Hv2 mutant 10 from SEQ ID NO.

[0154] 54. H3H_mutant_vl0.1_gc_boosted

[0155] SEQ ID NO. 71: Nucleotide sequence of GC-boosted nnH3Hv2 mutant 11 from SEQ ID NO.

[0156] 55. H3H_mutant_v 11. I gc boosted

[0157] SEQ ID NO. 72: Nucleotide sequence of GC-boosted nnH3Hv2 mutant 12 from SEQ ID NO.

[0158] 56. H3H_mutant_vl2.1_gc_boosted

[0159] SEQ ID NO. 73: Nucleotide sequence of GC-boosted nnH3Hv2 mutant 13 from SEQ ID NO.

[0160] 57. H3H_mutant_vl3.1_gc_boosted

[0161] SEQ ID NO. 74: Nucleotide sequence of GC-boosted nnH3Hv2 mutant 14 from SEQ ID NO.

[0162] 58. H3H_mutant_v 14. I gc boosted

[0163] SEQ ID NO. 75: Nucleotide sequence of GC-boosted nnH3Hv2 mutant 15 from SEQ ID NO.

[0164] 59. H3H_mutant_vl 5. l_gc_boosted

[0165] SEQ ID NO. 76: Nucleotide sequence of GC-boosted nnH3Hv2 mutant 16 from SEQ ID NO.

[0166] 60. H3H_mutant_vl6.1_gc_boosted

[0167] SEQ ID NO. 77: Nucleotide sequence of npgAgene in STARBURST (clone #1 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). -FB3_2Aified_di_mcu-l_npgA

[0168] SEQ ID NO. 78: Nucleotide sequence of GSG1 linker in STARBURST (clone #1 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). -FB3_2Aified_di_mcu-l_GSG_l

[0169] SEQ ID NO. 79: Nucleotide sequence of first LP4 / 2A linker in STARBURST (clone #1 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). -FB3_2Aified_di_mcu-l_LP42A_l

[0170] SEQ ID NO. 80: Nucleotide sequence of McitHispS gene in STARBURST (clone #1 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). -FB3_2Aified_di_mcu-l_McitHispS

[0171] SEQ ID NO. 81: Nucleotide sequence of GSG2 linker in STARBURST (clone #1 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). -FB3_2Aified_di_mcu-l_GSG_2

[0172] SEQ ID NO. 82: Nucleotide sequence of second LP4 / 2A linker in STARBURST (clone #1 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). -FB3_2Aified_di_mcu-l_LP42A_2

[0173] SEQ ID NO. 83: Nucleotide sequence of nnH3Hv2 gene in STARBURST (clone #1 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). -FB3_2Aified_di_mcu-l_nnH3H_v2

[0174] SEQ ID NO. 84: Nucleotide sequence of GSG3 linker in STARBURST (clone #1 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). -FB3_2Aified_di_mcu-l_GSG_3

[0175] Attorney Docket No.: 690104.0045

[0176] SEQ ID NO. 85: Nucleotide sequence of third LP4 / 2A linker in STARBURST (clone #1 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). -FB3 2Aified di mcu-1 LP42A 3

[0177] SEQ ID NO. 86: Nucleotide sequence of nnLUZv4 gene in STARBURST (clone #1 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). -FB3_2Aified_di_mcu-l_nnLuz_v4

[0178] SEQ ID NO. 87: Nucleotide sequence of GSG4 linker in STARBURST (clone #1 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). -FB3_2Aified_di_mcu-l_GSG_4

[0179] SEQ ID NO. 88: Nucleotide sequence of fourth LP4 / 2A linker in STARBURST (clone #1 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). -FB3_2Aified_di_mcu-l_LP42A_4

[0180] SEQ ID NO. 89: Nucleotide sequence of nnCPH gene in STARBURST (clone #1 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). -FB3_2Aified_di_mcu-l nnCPH

[0181] SEQ ID NO. 90: Nucleotide sequence of npgA gene in STARBURST (clone #2 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). - FB3_2Aified_di_mcu-2_npgA

[0182] SEQ ID NO. 91: Nucleotide sequence of GSG1 linker in STARBURST (clone #2 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). -FB3_2Aified_di_mcu-2_GSG_l

[0183] SEQ ID NO. 92: Nucleotide sequence of first LP4 / 2A linker in STARBURST (clone #2 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). - FB3_2Aified_di_mcu-2_LP42A_l

[0184] SEQ ID NO. 93: Nucleotide sequence of McitHispS gene in STARBURST (clone #2 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). - FB3_2Aified_di_mcu-2_McitHispS

[0185] SEQ ID NO. 94: Nucleotide sequence of GSG2 linker in STARBURST (clone #2 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). - FB3_2Aified_di_mcu-2_GSG_2

[0186] SEQ ID NO. 95: Nucleotide sequence of second LP4 / 2A linker in STARBURST (clone #2 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). - FB3_2Aified_di_mcu-2_LP42A_2

[0187] SEQ ID NO. 96: Nucleotide sequence of nnH3Hv2 linker in STARBURST (clone #2 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). - FB3_2Aified_di_mcu-2_nnH3H_v2

[0188] SEQ ID NO. 97: Nucleotide sequence of GSG3 linker in STARBURST (clone #2 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). - FB3_2Aified_di_mcu-2_GSG_3

[0189] SEQ ID NO. 98: Nucleotide sequence of third LP4 / 2A linker in STARBURST (clone #2 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). - FB3_2Aified_di_mcu-2_LP42A_3

[0190] SEQ ID NO. 99: Nucleotide sequence of nnLUZv4 gene in STARBURST (clone #2 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). - FB3_2Aified_di_mcu-2_nnLuz_v4

[0191] SEQ ID NO. 100: Nucleotide sequence of GSG4 linker in STARBURST (clone #2 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). - FB3_2Aified_di_mcu-2_GSG_4

[0192] SEQ ID NO. 101: Nucleotide sequence of fourth LP4 / 2A linker in STARBURST (clone #2 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). - FB3_2Aified_di_mcu-2_LP42A_4

[0193] Attorney Docket No.: 690104.0045

[0194] SEQ ID NO. 102: Nucleotide sequence of nnCPH gene in STARBURST (clone #2 - gene order: npgA; HispS; H3Hv2; LUZv4; CPH). - FB3 2Aified di mcu-2 nnCPH

[0195] SEQ ID NO. 103: Nucleotide sequence of McitHispS gene in STARBURST (clone #3 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-2_McitHispS

[0196] SEQ ID NO. 104: Nucleotide sequence of GSG1 linker in STARBURST (clone #3 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-2_GSG_l

[0197] SEQ ID NO. 105: Nucleotide sequence of first LP4 / 2A linker in STARBURST (clone #3 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-2_LP42A_l

[0198] SEQ ID NO. 106: Nucleotide sequence of npgA gene in STARBURST (clone #3 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-2_npgA

[0199] SEQ ID NO. 107: Nucleotide sequence of GSG2 linker in STARBURST (clone #3 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-2_GSG_2

[0200] SEQ ID NO. 108: Nucleotide sequence of second LP4 / 2A linker in STARBURST (clone #3 -gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-2_LP42A_2

[0201] SEQ ID NO. 109: Nucleotide sequence of nnH3Hv2 gene in STARBURST (clone #3 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-2_nnH3H_v2

[0202] SEQ ID NO. 110: Nucleotide sequence of GSG3 linker in STARBURST (clone #3 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-2_GSG_3

[0203] SEQ ID NO. 111: Nucleotide sequence of third LP4 / 2A linker in STARBURST (clone #3 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-2_LP42A_3

[0204] SEQ ID NO. 112: Nucleotide sequence of nnLUZzv4 gene in STARBURST (clone #3 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-2_nnLuz_v4

[0205] SEQ ID NO. 113: Nucleotide sequence of GSG4 linker in STARBURST (clone #3 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-2_GSG_4

[0206] SEQ ID NO. 114: Nucleotide sequence of fourth LP4 / 2A linker in STARBURST (clone #3 -gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-2_LP42A_4

[0207] SEQ ID NO. 115: Nucleotide sequence of nnCPH gene in STARBURST (clone #3 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-2_nnCPH

[0208] SEQ ID NO. 116: Nucleotide sequence of McitHispS gene in STARBURST (clone #4 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-3_McitHispS

[0209] SEQ ID NO. 117: Nucleotide sequence of GSG1 linker in STARBURST (clone #4 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-3_GSG_l

[0210] SEQ ID NO. 118: Nucleotide sequence of first LP4 / 2A linker in STARBURST (clone #4 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-3_LP42A_l

[0211] Attorney Docket No.: 690104.0045

[0212] SEQ ID NO. 119: Nucleotide sequence of npgA gene in STARBURST (clone #4 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A v2 di mcu-3 npgA

[0213] SEQ ID NO. 120: Nucleotide sequence of GSG2 linker in STARBURST (clone #4 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-3_GSG_2

[0214] SEQ ID NO. 121: Nucleotide sequence of second LP4 / 2A linker in STARBURST (clone #4 -gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-3_LP42A_2

[0215] SEQ ID NO. 122: Nucleotide sequence of nnH3Hv2 gene in STARBURST (clone #4 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-3_nnH3H_v2

[0216] SEQ ID NO. 123: Nucleotide sequence of GSG3 linker in STARBURST (clone #4 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-3_GSG_3

[0217] SEQ ID NO. 124: Nucleotide sequence of third LP4 / 2A linker in STARBURST (clone #4 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-3_LP42A_3

[0218] SEQ ID NO. 125: Nucleotide sequence of nnLUZv4 gene in STARBURST (clone #4 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-3_nnLuz_v4

[0219] SEQ ID NO. 126: Nucleotide sequence of GSG4 linker in STARBURST (clone #4 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-3_GSG_4

[0220] SEQ ID NO. 127: Nucleotide sequence of fourth LP4 / 2A linker in STARBURST (clone #4 -gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-3_LP42A_4

[0221] SEQ ID NO. 128: Nucleotide sequence of nnCPH gene in STARBURST (clone #4 - gene order: HispS; npgA; H3Hv2; LUZv4; CPH). - FBP3-2A_v2_di_mcu-3_nnCPH

[0222] SEQ ID NO. 129: Nucleotide sequence of nnLUZv4 gene in STARBURST (clone #5 - gene order: LUZv4; HispS; npgA; H3Hv2; CPH). - FBP3_2A_v3_di_mcu-1_nnLuz_v4

[0223] SEQ ID NO. 130: Nucleotide sequence of GSG1 linker in STARBURST (clone #5 - gene order: LUZv4; HispS; npgA; H3Hv2; CPH). - FBP3_2A_v3_di_mcu-1_GSG_1

[0224] SEQ ID NO. 131: Nucleotide sequence of first LP4 / 2A linker in STARBURST (clone #5 - gene order: LUZv4; HispS; npgA; H3Hv2; CPH). - FBP3_2A_v3_di_mcu-1_LP42A_1

[0225] SEQ ID NO. 132: Nucleotide sequence of McitHispS gene in STARBURST (clone #5 - gene order: LUZv4; HispS; npgA; H3Hv2; CPH). - FBP3_2A_v3_di_mcu-1_McitHispS

[0226] SEQ ID NO. 133: Nucleotide sequence of GSG2 linker in STARBURST (clone #5 - gene order: LUZv4; HispS; npgA; H3Hv2; CPH). - FBP3_2A_v3_di_mcu-1_GSG_2

[0227] SEQ ID NO. 134: Nucleotide sequence of second LP4 / 2A linker gene in STARBURST (clone #5 -gene order: LUZv4; HispS; npgA; H3Hv2; CPH). - FBP3_2A_v3_di_mcu-1_LP42A_2

[0228] SEQ ID NO. 135: Nucleotide sequence of npgA gene in STARBURST (clone #5 - gene order: LUZv4; HispS; npgA; H3Hv2; CPH). - FBP3_2A_v3_di_mcu-1_npgA

[0229] Attorney Docket No.: 690104.0045

[0230] SEQ ID NO. 136: Nucleotide sequence of GSG3 linker in STARBURST (clone #5 - gene order: LUZv4; HispS; npgA; H3Hv2; CPH). - FBP3_2A_v3_di_mcu-1_GSG_3

[0231] SEQ ID NO. 137: Nucleotide sequence of third LP4 / 2A linker in STARBURST (clone #5 - gene order: LUZv4; HispS; npgA; H3Hv2; CPH). - FBP3_2A_v3_di_mcu-1_LP42A_3

[0232] SEQ ID NO. 138: Nucleotide sequence of nnH3Hv2 gene in STARBURST (clone #5 - gene order: LUZv4; HispS; npgA; H3Hv2; CPH). - FBP3_2A_v3_di_mcu-1_nnH3H_v2

[0233] SEQ ID NO. 139: Nucleotide sequence of GSG4 linker in STARBURST (clone #5 - gene order: LUZv4; HispS; npgA; H3Hv2; CPH). - FBP3_2A_v3_di_mcu-1_GSG_4

[0234] SEQ ID NO. 140: Nucleotide sequence of fourth LP4 / 2A linker in STARBURST (clone #5 - gene order: LUZv4; HispS; npgA; H3Hv2; CPH). - FBP3_2A_v3_di_mcu-1_LP42A_4

[0235] SEQ ID NO. 141: Nucleotide sequence of nnCPH gene in STARBURST (clone #5 - gene order: LUZv4; HispS; npgA; H3Hv2; CPH). - FBP3_2A_v3_di_mcu-1_nnCPH

[0236] SEQ ID NO. 142: Nucleotide sequence of McitHispS gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 48% GC content.

[0237] STARBURST 48 gc gc3 s 38 McitHispS

[0238] SEQ ID NO. 143: Nucleotide sequence of GSG1 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 48% GC content.

[0239] STARBURST 48 gc gc3 s 38 GSG 1

[0240] SEQ ID NO. 144: Nucleotide sequence of first LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 48% GC content.

[0241] STARBURST 48 gc gc3 s 38 LP42A 1

[0242] SEQ ID NO. 145: Nucleotide sequence of npgA gene in STARBURST (design #2 gene order:

[0243] HispS; npgA; H3Hv2; LUZv4; CPH) with 48% GC content.

[0244] STARBURST_48_gc_gc3 s_38_npgA

[0245] SEQ ID NO. 146: Nucleotide sequence of GSG2 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 48% GC content.

[0246] STARBURST_48_gc_gc3 s_38_GSG_2

[0247] SEQ ID NO. 147: Nucleotide sequence of second LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 48% GC content.

[0248] STARBURST_48_gc_gc3 s_38 LP42A 2

[0249] SEQ ID NO. 148: Nucleotide sequence of nnH3Hv2 gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 48% GC content.

[0250] STARBURST_48_gc_gc3 s_38_nnH3H_v2

[0251] SEQ ID NO. 149: Nucleotide sequence of GSG3 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 48% GC content.

[0252] STARBURST_48_gc_gc3 s_38_GSG_3

[0253] Attorney Docket No.: 690104.0045

[0254] SEQ ID NO. 150: Nucleotide sequence of third LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 48% GC content.

[0255] STARBURST_48_gc_gc3 s_38 LP42A 3

[0256] SEQ ID NO. 151: Nucleotide sequence of nnLUZv4 gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 48% GC content.

[0257] STARBURST_48_gc_gc3 s_38_nnLuz_v4

[0258] SEQ ID NO. 152: Nucleotide sequence of GSG4 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 48% GC content.

[0259] STARBURST_48_gc_gc3 s_38 GSG 4

[0260] SEQ ID NO. 153: Nucleotide sequence of fourth LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 48% GC content.

[0261] STARBURST_48_gc_gc3 s_38 LP42A 4

[0262] SEQ ID NO. 154: Nucleotide sequence of nnCPH gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 48% GC content.

[0263] STARBURST_48_gc_gc3 s_38_nnCPH

[0264] SEQ ID NO. 155: Nucleotide sequence of McitHispS gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 53% GC content.

[0265] STARBURST_53gc_gc3s_50_McitHispS

[0266] SEQ ID NO. 156: Nucleotide sequence of GSG1 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 53% GC content.

[0267] STARBURST_53gc_gc3 s_50_GSG_l

[0268] SEQ ID NO. 157: Nucleotide sequence of first LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 53% GC content.

[0269] STARBURST_53gc_gc3 s_50_LP42A_l

[0270] SEQ ID NO. 158: Nucleotide sequence of npgA gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 53% GC content.

[0271] STARBURST_53gc_gc3 s_50_npgA

[0272] SEQ ID NO. 159: Nucleotide sequence of GSG2 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 53% GC content.

[0273] STARBURST_53gc_gc3 s_50_GSG_2

[0274] SEQ ID NO. 160: Nucleotide sequence of second LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 53% GC content.

[0275] STARBURST_53gc_gc3 s_50_LP42A_2

[0276] SEQ ID NO. 161: Nucleotide sequence of nnH3Hv2 gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 53% GC content.

[0277] STARBURST_53gc_gc3 s_50_nnH3H_v2

[0278] Attorney Docket No.: 690104.0045

[0279] SEQ ID NO. 162: Nucleotide sequence of GSG3 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 53% GC content.

[0280] S TARBURS T_53 gc_gc3 s_50_GSG_3

[0281] SEQ ID NO. 163: Nucleotide sequence of third LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 53% GC content.

[0282] S TARBURS T_53 gc_gc3 s_50_LP42A_3

[0283] SEQ ID NO. 164: Nucleotide sequence of nnLUZv4 gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 53% GC content.

[0284] S TARBURS T_53 gc_gc3 s_50_nnLuz_v4

[0285] SEQ ID NO. 165: Nucleotide sequence of GSG4 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 53% GC content.

[0286] S TARBURS T_53 gc_gc3 s_50_GSG_4

[0287] SEQ ID NO. 166: Nucleotide sequence of fourth LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 53% GC content.

[0288] STARBURST_53gc_gc3 s_50_LP42A_4

[0289] SEQ ID NO. 167: Nucleotide sequence of nnCPH gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 53% GC content.

[0290] STARBURST_53gc_gc3 s_50_nnCPH

[0291] SEQ ID NO. 168: Nucleotide sequence of McitHipS gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 55% GC content.

[0292] STARBURST_55gc_gc3s_55_McitHispS

[0293] SEQ ID NO. 169: Nucleotide sequence of GSG1 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 55% GC content.

[0294] STARBURST_55gc_gc3s_55_GSG_l

[0295] SEQ ID NO. 170: Nucleotide sequence of first LP4 / 2A linker

[0296] STARBURST_55gc_gc3 s_55 LP42A 1

[0297] SEQ ID NO. 171: Nucleotide sequence of npgA gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 55% GC content.

[0298] STARBURST_55gc_gc3 s_55_npgA

[0299] SEQ ID NO. 172: Nucleotide sequence of GSG2 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 55% GC content.

[0300] STARBURST_55gc_gc3 s_55 GSG 2

[0301] SEQ ID NO. 173: Nucleotide sequence of second LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 55% GC content.

[0302] STARBURST_55gc_gc3 s_55 LP42A 2

[0303] Attorney Docket No.: 690104.0045

[0304] SEQ ID NO. 174: Nucleotide sequence of nnH3Hv2 gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 55% GC content.

[0305] STARBURST_55gc_gc3 s_55_nnH3H_v2

[0306] SEQ ID NO. 175: Nucleotide sequence of GSG3 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 55% GC content.

[0307] STARBURST_55gc_gc3 s_55 GSG 3

[0308] SEQ ID NO. 176: Nucleotide sequence of third LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 55% GC content.

[0309] STARBURST_55gc_gc3 s_55 LP42A 3

[0310] SEQ ID NO. 177: Nucleotide sequence of nnLUZv4 gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 55% GC content.

[0311] S TARBURS T_55 gc_gc3 s_55_nnLuz_v4

[0312] SEQ ID NO. 178: Nucleotide sequence of GSG4 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 55% GC content.

[0313] STARBURST_55gc_gc3 s_55 GSG 4

[0314] SEQ ID NO. 179: Nucleotide sequence of fourth LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 55% GC content.

[0315] STARBURST_55gc_gc3 s_55 LP42A 4

[0316] SEQ ID NO. 180: Nucleotide sequence of nnCPH gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 55% GC content.

[0317] STARBURST_55gc_gc3 s_55_nnCPH

[0318] SEQ ID NO. 181: Nucleotide sequence of McitHispS gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 57% GC content.

[0319] STARBURST_57gc_gc3 s_6 I McitHispS

[0320] SEQ ID NO. 182: Nucleotide sequence of GSG1 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 57% GC content.

[0321] STARBURST_57gc_gc3 s_61 GSG 1

[0322] SEQ ID NO. 183: Nucleotide sequence of first LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 57% GC content.

[0323] STARBURST_57gc_gc3 s_61 LP42A 1

[0324] SEQ ID NO. 184: Nucleotide sequence of npgA gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 57% GC content.

[0325] STARBURST_57gc_gc3 s_6 I npgA

[0326] SEQ ID NO. 185: Nucleotide sequence of GSG2 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 57% GC content.

[0327] STARBURST_57gc_gc3 s_61 GSG 2

[0328] Attorney Docket No.: 690104.0045

[0329] SEQ ID NO. 186: Nucleotide sequence of second LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 57% GC content.

[0330] STARBURST_57gc_gc3 s_61 LP42A 2

[0331] SEQ ID NO. 187: Nucleotide sequence of nnH3Hv2 gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 57% GC content.

[0332] STARBURST_57gc_gc3 s_6 l_nnH3H_v2

[0333] SEQ ID NO. 188: Nucleotide sequence of GSG3 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 57% GC content.

[0334] STARBURST_57gc_gc3 s_61 GSG 3

[0335] SEQ ID NO. 189: Nucleotide sequence of third LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 57% GC content.

[0336] STARBURST_57gc_gc3 s_61 LP42A 3

[0337] SEQ ID NO. 190: Nucleotide sequence of nnLUZv4 gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 57% GC content.

[0338] STARBURST_57gc_gc3 s_6 l_nnLuz_v4

[0339] SEQ ID NO. 191: Nucleotide sequence of GSG4 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 57% GC content.

[0340] STARBURST_57gc_gc3 s_61 GSG 4

[0341] SEQ ID NO. 192: Nucleotide sequence of fourth LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 57% GC content.

[0342] STARBURST_57gc_gc3 s_61_LP42A_4

[0343] SEQ ID NO. 193: Nucleotide sequence of nnCPH gene in STARBURST (design #2 gene order: HispS; npgA; content.

[0344] STARBURST

[0345]

[0346] SEQ ID NO. 194: Nucleotide sequence of McitHispS gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 59% GC content.

[0347] STARBURST_59gc_gc3 s_66_McitHispS

[0348] SEQ ID NO. 195: Nucleotide sequence of GSG1 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 59% GC content.

[0349] STARBURST_59gc_gc3 s_66_GSG_l

[0350] SEQ ID NO. 196: Nucleotide sequence of first LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 59% GC content.

[0351] STARBURST_59gc_gc3 s_66_LP42A_l

[0352] SEQ ID NO. 197: Nucleotide sequence of npgA gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 59% GC content.

[0353] STARBURST_59gc_gc3 s_66_npgA

[0354] Attorney Docket No.: 690104.0045

[0355] SEQ ID NO. 198: Nucleotide sequence of GSG2 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 59% GC content.

[0356] STARBURST_59gc_gc3s_66_GSG_2

[0357] SEQ ID NO. 199: Nucleotide sequence of second LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 59% GC content.

[0358] STARBURST_59gc_gc3s_66_LP42A_2

[0359] SEQ ID NO. 200: Nucleotide sequence of nnH3Hv2 in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 59% GC content.

[0360] STARBURST_59gc_gc3s_66_nnH3H_v2

[0361] SEQ ID NO. 201: Nucleotide sequence of GSG3 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 59% GC content.

[0362] STARBURST_59gc_gc3s_66_GSG_3

[0363] SEQ ID NO. 202: Nucleotide sequence of third LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 59% GC content.

[0364] STARBURST_59gc_gc3s_66_LP42A_3

[0365] SEQ ID NO. 203: Nucleotide sequence of nnLUZv4 gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 59% GC content.

[0366] STARBURST_59gc_gc3s_66_nnLuz_v4

[0367] SEQ ID NO. 204: Nucleotide sequence of GSG4 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 59% GC content.

[0368] STARBURST_59gc_gc3s_66_GSG_4

[0369] SEQ ID NO. 205: Nucleotide sequence of fourth LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 59% GC content.

[0370] STARBURST_59gc_gc3s_66_LP42A_4

[0371] SEQ ID NO. 206: Nucleotide sequence of nnCPH gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 59% GC content.

[0372] STARBURST_59gc_gc3s_66_nnCPH

[0373] SEQ ID NO. 207: Nucleotide sequence of McitHispS gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 60% GC content.

[0374] STARBURST_60gc_gc3s_70_McitHispS

[0375] SEQ ID NO. 208: Nucleotide sequence of GSG1 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 60% GC content.

[0376] STARBURST_60gc_gc3s_70_GSG_1

[0377] SEQ ID NO. 209: Nucleotide sequence of first LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 60% GC content.

[0378] STARBURST_60gc_gc3s_70_LP42A_1

[0379] Attorney Docket No.: 690104.0045

[0380] SEQ ID NO. 210: Nucleotide sequence of npgA gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 60% GC content.

[0381] STARBURST_60gc_gc3s_70_npgA

[0382] SEQ ID NO. 211: Nucleotide sequence of GSG2 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 60% GC content.

[0383] STARBURST_60gc_gc3s_70_GSG_2

[0384] SEQ ID NO. 212: Nucleotide sequence of second LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 60% GC content.

[0385] STARBURST_60gc_gc3s_70_LP42A_2

[0386] SEQ ID NO. 213: Nucleotide sequence of nnH3Hv2 gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 60% GC content.

[0387] STARBURST_60gc_gc3s_70_nnH3H_v2

[0388] SEQ ID NO. 214: Nucleotide sequence of GSG3 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 60% GC content.

[0389] STARBURST_60gc_gc3s_70_GSG_3

[0390] SEQ ID NO. 215: Nucleotide sequence of third LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 60% GC content.

[0391] STARBURST_60gc_gc3s_70_LP42A_3

[0392] SEQ ID NO. 216: Nucleotide sequence of nnLUZv4 in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 60% GC content.

[0393] STARBURST_60gc_gc3s_70_nnLuz_v4

[0394] SEQ ID NO. 217: Nucleotide sequence of GSG4 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 60% GC content.

[0395] STARBURST_60gc_gc3s_70_GSG_4

[0396] SEQ ID NO. 218: Nucleotide sequence of fourth LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 60% GC content.

[0397] STARBURST_60gc_gc3s_70_LP42A_4

[0398] SEQ ID NO. 219: Nucleotide sequence of nnCPH gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 60% GC content.

[0399] STARBURST_60gc_gc3s_70_nnCPH

[0400] SEQ ID NO. 220: Nucleotide sequence of McitHispS gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 62% GC content.

[0401] STARBURST_62gc_gc3s_75_McitHispS

[0402] SEQ ID NO. 221: Nucleotide sequence of GSG1 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 62% GC content.

[0403] STARBURST_62gc_gc3s_75_GSG_1

[0404] Attorney Docket No.: 690104.0045

[0405] SEQ ID NO. 222: Nucleotide sequence of first LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 62% GC content.

[0406] STARBURST_62gc_gc3s_75_LP42A_1

[0407] SEQ ID NO. 223: Nucleotide sequence of npgA gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 62% GC content.

[0408] STARBURST_62gc_gc3s_75_npgA

[0409] SEQ ID NO. 224: Nucleotide sequence of GSG2 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 62% GC content.

[0410] STARBURST_62gc_gc3s_75_GSG_2

[0411] SEQ ID NO. 225: Nucleotide sequence of second LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 62% GC content.

[0412] STARBURST_62gc_gc3s_75_LP42A_2

[0413] SEQ ID NO. 226: Nucleotide sequence of nnH3Hv2 gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 62% GC content.

[0414] STARBURST_62gc_gc3s_75_nnH3H_v2

[0415] SEQ ID NO. 227: Nucleotide sequence of GSG3 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 62% GC content.

[0416] STARBURST_62gc_gc3s_75_GSG_3

[0417] SEQ ID NO. 228: Nucleotide sequence of third LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 62% GC content.

[0418] STARBURST_62gc_gc3s_75_LP42A_3

[0419] SEQ ID NO. 229: Nucleotide sequence of nnLUZv4 gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 62% GC content.

[0420] STARBURST_62gc_gc3s_75_nnLuz_v4

[0421] SEQ ID NO. 230: Nucleotide sequence of GSG4 linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 62% GC content.

[0422] STARBURST_62gc_gc3s_75_GSG_4

[0423] SEQ ID NO. 231: Nucleotide sequence of fourth LP4 / 2A linker in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 62% GC content.

[0424] STARBURST_62gc_gc3s_75_LP42A_4

[0425] SEQ ID NO. 232: Nucleotide sequence of nnCPH gene in STARBURST (design #2 gene order: HispS; npgA; H3Hv2; LUZv4; CPH) with 62% GC content.

[0426] STARBURST_62gc_gc3s_75_nnCPH

[0427] SEQ ID NO. 233: Nucleotide sequence of STARBURST with nnLUZv4 gene removed (clone #3 - gene order: HispS; npgA; H3Hv2; removed - LUZv4; CPH).

[0428] STARBURST_HispS_npgA_H3H_Luz_CPH_vl_w_LUZ_removed

[0429] Attorney Docket No.: 690104.0045

[0430] SEQ ID NO. 234: Nucleotide sequence of STARBURST with nnH3Hv2 gene removed (clone #3 - gene order: HispS; npgA; H3Hv2 - removed; LUZv4; CPH).

[0431] STARBURST_HispS_npgA_H3H_Luz_CPH_vl_w_H3H_removed

[0432] SEQ ID NO. 235: Nucleotide sequence of STARBURST with nnCPH gene removed (clone #3 -gene order: HispS; npgA; H3Hv2 - removed; LUZv4; CPH - removed).

[0433] STARBURST_HispS_npgA_H3H_Luz_CPH_vl_nnCPH_removed

[0434] SEQ ID NO. 236: Nucleotide sequence of STARBURST with HispS gene removed (clone #3 -gene order: HispS - removed; npgA; H3Hv2 - removed; LUZv4; CPH).

[0435] STARBURST_HispS_npgA_H3H_Luz_CPH_vl_HispS_removed

[0436] SEQ ID NO. 237: Amino acid sequence of HispS protein in STARBURST clones 1-5. mcitHispS aa

[0437] SEQ ID NO. 238: Amino acid sequence of npgA protein in STARBURST clones 1-5. npgA aa

[0438] SEQ ID NO. 239: Amino acid sequence of H3Hv2 protein in STARBURST clones 1-5. nnH3H v2 aa

[0439] SEQ ID NO. 240: Amino acid sequence of Luzv4 protein in STARBURST clones 1-5. nnLuz_v4 aa

[0440] SEQ ID NO. 241: Amino acid sequence of CPH protein in STARBURST clones 1-5. nnCPH aa

[0441] SEQ ID NO. 242: Nucleotide sequence of mcitHispS gene in STARBURST clones 1-5 prior to any codon optimization, intron removal, or GC content alteration. - mcitHispS dna

[0442] SEQ ID NO. 243: Nucleotide sequence of npgA gene in STARBURST clones 1-5 prior to any codon optimization, intron removal, or GC content alteration. - npgA dna

[0443] SEQ ID NO. 244: Nucleotide sequence of nnH3Hv2 gene in STARBURST clones 1-5 prior to any codon optimization, intron removal, or GC content alteration. - nnH3H_v2 dna

[0444] SEQ ID NO. 245: Nucleotide sequence of nnLuzv4 gene in STARBURST clones 1-5 prior to any codon optimization, intron removal, or GC content alteration. - nnLuz_v4 dna

[0445] SEQ ID NO. 246: Nucleotide sequence of nnCPH gene in STARBURST clones 1-5 prior to any codon optimization, intron removal, or GC content alteration. - nnCPH dna

[0446] SEQ ID NO. 247: Amino acid sequence of nnLuzv4 mutant 1 protein.

[0447] STARBURST_nnLUZ_mut_1.1

[0448] SEQ ID NO. 248: Amino acid sequence of nnLuzv4 mutant 2 protein.

[0449] STARBURST_nnLUZ_mut_2.1

[0450] SEQ ID NO. 249: Amino acid sequence of nnLuzv4 mutant 3 protein.

[0451] STARBURST_nnLUZ_mut_3.1

[0452] Attorney Docket No.: 690104.0045

[0453] SEQ ID NO. 250: Amino acid sequence of nnLuzv4 mutant 4 protein.

[0454] STARBURST_nnLUZ_mut_4.1

[0455] SEQ ID NO. 251: Amino acid sequence of nnLuzv4 mutant 5 protein.

[0456] STARBURST_nnLUZ_mut_5.1

[0457] SEQ ID NO. 252: Amino acid sequence of nnLuzv4 mutant 6 protein.

[0458] STARBURST_nnLUZ_mut_6.1

[0459] SEQ ID NO. 253: Amino acid sequence of nnLuzv4 mutant 7 protein.

[0460] STARBURST_nnLUZ_mut_7.1

[0461] SEQ ID NO. 254: Amino acid sequence of nnLuzv4 mutant 8 protein.

[0462] STARBURST_nnLUZ_mut_8.1

[0463] SEQ ID NO. 255: Amino acid sequence of nnLuzv4 mutant 9 protein.

[0464] STARBURST_nnLUZ_mut_9.1

[0465] SEQ ID NO. 256: Amino acid sequence of nnLuzv4 mutant 10 protein.

[0466] STARBURST_nnLUZ_mut_10.1

[0467] SEQ ID NO. 257: Amino acid sequence of nnLuzv4 mutant 11 protein.

[0468] STARBURST_nnLUZ_mut_11.1

[0469] SEQ ID NO. 258: Amino acid sequence of nnLuzv4 mutant 12 protein.

[0470] STARBURST_nnLUZ_mut_12.1

[0471] SEQ ID NO. 259: Amino acid sequence of nnLuzv4 mutant 13 protein.

[0472] STARBURST_nnLUZ_mut_13.1

[0473] SEQ ID NO. 260: Amino acid sequence of nnLuzv4 mutant 14 protein.

[0474] STARBURST_nnLUZ_mut_14.1

[0475] SEQ ID NO. 261: Amino acid sequence of nnLuzv4 mutant 15 protein.

[0476] STARBURST_nnLUZ_mut_15.1

[0477] SEQ ID NO. 262: Amino acid sequence of nnLuzv4 mutant 16 protein.

[0478] STARBURST_nnLUZ_mut_16.1

[0479] SEQ ID NO. 263: Amino acid sequence of H3Hv2 mutant 1 protein. H3H_mutant_vl.l

[0480] SEQ ID NO. 264: Amino acid sequence of H3Hv2 mutant 2 protein. H3H_mutant_v2.1

[0481] SEQ ID NO. 265: Amino acid sequence of H3Hv2 mutant 3 protein. H3H_mutant_v3.1

[0482] SEQ ID NO. 266: Amino acid sequence of H3Hv2 mutant 4 protein. H3H_mutant_v4.1

[0483] SEQ ID NO. 267: Amino acid sequence of H3Hv2 mutant 5 protein. H3H_mutant_v5.1

[0484] SEQ ID NO. 268: Amino acid sequence of H3Hv2 mutant 6 protein. H3H_mutant_v6.1

[0485] SEQ ID NO. 269: Amino acid sequence of H3Hv2 mutant 7 protein. H3H_mutant_v7.1Attorney Docket No.: 690104.0045

[0486] SEQ ID NO. 270: Amino acid sequence of H3Hv2 mutant 8 protein. H3H_mutant_v8.1 SEQ ID NO. 271: Amino acid sequence of H3Hv2 mutant 9 protein. H3H_mutant_v9.1 SEQ ID NO. 272: Amino acid sequence of H3Hv2 mutant 10 protein. H3H_mutant_vl0.1

[0487] SEQ ID NO. 273: Amino acid sequence of H3Hv2 mutant 11 protein. H3H_mutant_vll.l

[0488] SEQ ID NO. 274: Amino acid sequence of H3Hv2 mutant 12 protein. H3H_mutant_vl2.1

[0489] SEQ ID NO. 275: Amino acid sequence of H3Hv2 mutant 13 protein. H3H_mutant_vl3.1

[0490] SEQ ID NO. 276: Amino acid sequence of H3Hv2 mutant 14 protein. H3H_mutant_v14.1

[0491] SEQ ID NO. 277: Amino acid sequence of H3Hv2 mutant 15 protein. H3H_mutant_vl5.1

[0492] SEQ ID NO. 278: Amino acid sequence of H3Hv2 mutant 16 protein. H3H_mutant_vl6.1

[0493] SEQ ID NO. 279: Amino acid sequence of nnH3H protein.

[0494] SEQ ID NO. 280: Amino acid sequence of nnLuz protein.

[0495] Detailed Description:

[0496] Combining multiple genes of the bioluminescence pathway in an expression cassette could enhance the ease with which transgenic organisms (e.g., transgenic plants and animals) can be generated and / or could enhance expression of the genes and / or proteins of the pathway. In some embodiments, all genes of a bioluminescence pathway could be combined into a single expression cassette. For example, the genes of the fungal bioluminescence pathway (HispS, H3H, LUZ, CPH, and npgA) could all be included in a single bioluminescence expression cassette. Alternatively, some portions of the total genes (e.g., 2, 3, or 4 genes) of the pathway could be included in a single expression cassette and the remaining genes could be included separately or combined into a second expression cassette. For example, four genes could be included on one cassette and the fifth gene could be introduced separately; three genes could be included on one cassette and the remaining two genes could be introduced separately; three genes could be included on one cassette and the remaining genes could be included on a second expression cassette; or two genes could be included on one cassette and the remaining genes could be introduced separately. Any of the genes of the pathway could be included either separately or in one or the other expression cassette. In certain examples, the bioluminescent transgene cassette may comprise a nucleotide sequence selected from SEQ ID NOs: 1-12 or 233-236.

[0497] Attorney Docket No.: 690104.0045

[0498] When referencing the expression cassette, we refer herein to a nucleic acid that contains two or more genes under the control of a single promoter such that those two or more genes are co-transcribed, i.e., they are included in the same resulting transcript. Such genes may be separated by one or more linkers that are self-cleaving linkers or protein cleavage sites. For example the linker may comprise LP4, 2A, GSG, or combinations thereof, such as the linkers of SEQ ID NOs: 78-79, 81-82, 84-85, 87-88, 91-92, 94-95, 97-98, 100-101, 104-105, 107-108, 110- 111, 113-114, 117-118, 120-121, 123-124, 126-127, 130-131, 133-134, 136-137, 139-140, 143-144, 146-147, 149-150, 152-153, 156-157, 159-160, 162-163, 165-166, 169-170, 172-173, 175-176, 178-179, 182-183, 185-186, 188-189, 191-192, 195-196, 198-199, 201-202, 204-205, 208-209, 211-212, 214-215, 217-218, 221-222, 224-225, 227-228, and 230-231.

[0499] The expression cassette may be included on a nucleic acid that also contains other genes (e g., one or more of the remaining genes of the bioluminescence pathway) under the control of a separate promoter. For example, a single nucleic acid could include an expression cassette that includes 2, 3, or 4 genes of the bioluminescence pathway along with a second expression cassette containing two or more genes of the bioluminescence pathway and / or one or more separate genes of the bioluminescence pathway. In some examples, an expression cassette or a nucleic acid may contain more than one copy of one or more genes of the bioluminescence pathway

[0500] In some embodiments, one or more genes of the bioluminescence pathway were altered to accomplish one or more of: (1) codon optimization for a particular organism of choice (e.g., the organism into which the bioluminescence pathway genes are to be introduced), (2) systematic computational identification and removal of predicted intron donor and acceptor sites, and (3) optimization of GC content, for example by increasing GC content to at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, or more. In certain examples, the variant nucleotide sequences of the bioluminescence pathway genes (e.g., HispS, H3H, LUZ, CPH, and / or npgA) comprise a nucleotide sequence selected from the group consisting of SEQ ID NOs: 77, 80, 83, 86, 89-90, 93, 96, 99, 102-103, 106, 109,

[0501] 112, 115-116, 119, 122, 125, 128-129, 132, 135, 138, 141-142, 145, 148, 151, 154-155, 158, 161, 164, 167-168, 171, 174, 177, 180-181, 184, 187, 190, 193-194, 197, 200, 203, 206-207, 210, 213, 216, 219-220, 223, 226, 229, and 242-246.

[0502] Attorney Docket No.: 690104.0045

[0503] The genes of the bioluminescence pathway (whether it is multiple genes in an expression cassette or individual genes) may be under the control of any suitable promoter and enhancer elements. Many such promoters are well known and persons of ordinary skill in the art would be able to readily select suitable elements for use in their particular situation. For example, a constitutive promoter useful in the particular organism of interest may be used. Alternatively, a promoter that is temporally and / or spatially restricted may be used, such as a promoter that is active only in certain tissue types (e.g., flowers or leaves) or certain times of the day or year.

[0504] In certain embodiments, one or more of the genes of the bioluminescence pathway (e.g., HispS, H3H, LUZ, CPH, and / or npgA) may be altered such that a mutant protein is produced. In such a case, the variant gene possesses a nucleotide sequence that, when translated, produces a variant protein with an amino acid sequence that differs from the wildtype amino acid sequence. In certain examples, the variant nucleotide sequence that produces a mutant protein of the bioluminescence pathway (e.g., HispS, H3H, LUZ, CPH, and / or npgA) comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 13-76. In other examples, the mutant protein that is produced comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 247-278.

[0505] In certain embodiments, the present application describes a bioluminescent transgene cassette containing the bioluminescence pathway genes as described herein.

[0506] In other embodiments, the present application describes a method of producing a bioluminescent organism by inserting into a cell or organism the bioluminescent transgene cassette and / or bioluminescence pathway genes described herein to produce heterologous expression of the bioluminescence pathway genes within such organism. Such methods can utilize any known method for inserting the cassette and / or bioluminescence pathway genes into such organism, including any known method that produces transient or stable expression within such organism. Such methods are well known in the art.

[0507] In further embodiments, the present application describes a bioluminescent organism that contains the bioluminescent transgene cassette and / or bioluminescence pathway genes described herein and / or that were produced by the methods described herein. In certain examples, such organism may be an animal or plant species. Examples of suitable animals include fish, arthropods, and mammals. Examples of suitable plants include ornamental plants, such as

[0508] Attorney Docket No.: 690104.0045

[0509] flowering plants. Specific examples may include petunias, impatiens, roses, begonias, and the like.

[0510]

[0511] To summarize some of the examples described herein, we created a single expression cassette containing all genes of the bioluminescence pathway, with those genes separated by self¬ cleaving linkers (such that a single transcript is produced during transcription that then results in five separate protein products when that transcript is translated. We synthesized five different single-transcript autonomously bioluminescent reporters (STARBURSTs) that link the five genes (HipsS, H3H Luz, CPH, npgA) of the fungal bioluminescence pathway via ribosomal skipping LP4 / 2A sequences into a 9.5 kb transcript (SEQ ID NOS: 1-5). The five STARBURSTs were rira / i / / zs / .s-codon-matched and lacked any predicted acceptor or donor sites. (Figure 3). The “Firefly petunia,” a commercially available autoluminescent plant developed using the FBP pathway, was used as a benchmark for STARBURST's performance, and the STARBURST showed brighter luminescence. (Figure 4).

[0512] To facilitate iterative genetic design, we developed iggypop - indexed Golden Gate gene assembly from PCR amplified oligonucleotide pools - a simple computational-experimental pipeline for building complex genes and sequences. Iggypop leverages oligonucleotide pools, Golden Gate assembly, and amplicon sequencing to streamline the creation of multi-kilobase DNA fragments. Iggypop allowed us to synthesize and test multiple different orders of the pathway’s genes in the constructs and uncover a substantial impact of GC content on the expression of synthetic plant genetic parts. We used iggypop to define an optimal gene order that places the largest gene, HispS, first, followed by the pathway’s other enzymes in their biosynthetic sequence ( pgA, II3H, Luz, and CPH)

[0513] We also synthesized several STARBURSTs with varying GC content (SEQ ID NOS: 6- 12). These GC -boosted STARBURSTs were synthesized with the five genes of the fungal bioluminescence pathway in the optimal gene order that was determined using iggypop (HispS, npgA. H3H, Luz, and CPH). The GC -boosted STARBURSTs were rad / t / o^szs-codon-matched and lacked any predicted intron acceptor or donor sites. The GC -boosted STARBURSTs (SEQ ID NOS: 7-12), were an order of magnitude brighter than a 48% GC content version (SEQ ID

[0514] Attorney Docket No.: 690104.0045

[0515] NO: 4), showing that GC content can be a beneficial strategy for achieving high-level expression of synthetic polycistronic genes in planta.

[0516] Our polycistronic STARBURST sequence links the five genes of the autobioluminescense pathway via LP4 / 2A ribosomal skipping peptides into a 9.5 kb transcript. To our knowledge, most plant genes are linked by 2A peptides expressed in planta. Prior work has linked up to four carotenoid biosynthetic genes in bi-, tri-, and quad-ci stronic transcripts; while the bicistronic and tricistronic constructs generally produced the expected proteins, the 4.1 kb quad-cistronic construct showed incomplete cleavage of its last two encoded proteins and reduced carotenoid production (7). In K. phaffi, up to nine genes have been successfully linked in a 12 kb coding sequence (9). Our results suggest that longer and more complex polycistronic transcripts should be possible in plants, and that such design can offer benefits from testing different gene orders and GC-contents.

[0517] Our initial RUBY and STARBURST genetic designs used dnachisel to match Arabidopsis codon usage, and from this, we observed large reductions in pigment and luminescence levels for coding sequences with low GC content.

[0518] Speculating that cryptic introns could reduce the function of synthetic genes, we compared three designed RUBY coding sequences with Arabidopsis-matched codon usage to versions in which candidate intron acceptor and donor junctions had been removed. These were predicted by Spliceator, a convolutional neural network trained on curated data from over 100 organisms that report 89-92% accuracy for plants (21). Despite these modifications, we did not observe apparent improvement in RUBY activity in “deintronized” transcripts. This implies that, in our system, if cryptic splicing occurs at all, it is at a level too low to be reflected in RUBY expression and may not be a generally useful approach; however, it could be more valuable as gene length and numbers of predicted junctions increase or as the accuracy of intron prediction for synthetic genes improves.

[0519] GC content was tuned using dnachisel functions called by iggypop using EnforceGCContent to optimize for a minimum specified GC content over a 60-base pair sliding window with match codon usage and an Arabidopsis codon table; this ensures that the amino acid sequences are not modified during the GC tuning. A 4x multiplier (boost) was applied to the EnforceGCContent optimization to ensure that GC content dominated the optimization relative to codon usage. The genes designed this way have more consistent GC content across their lengthAttorney Docket No.: 690104.0045

[0520] relative to genes codon optimized without GC tuning; this can be captured by calculating the coefficient of variance (CoV) of the GC content calculated for each window of the 60 base-pair sliding window used during optimization. (See Figure 5). High GC content STARBURST clones optimized using the approach described above have much greater uniformity in their GC content relative to genes designed to match Arabidopsis codon usage; the same trend holds for codon optimized RUBYs. (See Figure 5). Low CoVs, preferably less than 0.054 but ideally much lower are associated with high expression and a feature of genes optimized using the GC boosting approach outlined above. (See Figure 5). GC boosting reduces variability in GC content across gene length relative to matching codon usage. (See Figure 5).

[0521] Genes codon optimized by matching codon usage have higher variability in GC content relative to those optimized with GC boosting as described above. We first calculated GC content in 60-base sliding windows for each gene, yielding a set of raw GC values across its length. Next, a moving-average smoothing (window of 5) was applied to these values, replacing each point with the average of its neighbors to emphasize broader trends and reduce local noise. Each gene’s smoothed values were then normalized by dividing by that gene’s mean GC content, allowing direct comparisons across genes despite differences in baseline GC levels. Genes optimized with match codon usage (annotated with mcu) have much greater variability in GC content across their lengths than those with GC boosting, as indicated by the great spread around the normalized mean. (Figure 6).

[0522] Example 1: Gene assembly from oligo pools with iggypop

[0523] To empower large-scale gene synthesis projects and accelerate construct creation by direct synthesis, we created an open-source software tool and experimental gene-synthesis pipeline- / g>7?o?-which enables rapid gene assembly from oligonucleotide pool templates (Figure 7). Our approach is similar to recently described methods for gene synthesis from oligonucleotide pools (10, 11). The pipeline begins by computationally cutting input sequences into small fragments at sites with efficient 4-base high-fidelity overhang “hinges” for reassembly by Golden Gate cloning; experimentally determined all-by-all overhang ligation data (12) is used to guide the overhang selection. High-fidelity overhangs are selected from a large collection of pre-computed high-fidelity hingesets. Once hinged, the fragments are appended with type IIS restriction cut sequences and indexed with unique primer-binding sequences (indexes) to enableAttorney Docket No.: 690104.0045

[0524] all fragments for a target to be amplified from oligonucleotide pools in a single-tube reaction. Error-free clones are identified after Golden Gate assembly by sequencing barcoded amplicons. The code for this pipeline is available on GitHub.

[0525] For the work described here, we synthesized the fragments as -250 bp oligonucleotides; 50 bp of each is used for index and cut sequences. Once assembled and cloned, colonies are sequenced using a nanopore amplicon sequencing pipeline to identify the final sequence-verified clones.

[0526] To test the iggypop pipeline (Figure 8A), we designed and synthesized 52 phylogenetically diverse plant transcription factors. (Figure 8B). The set had a median size of 923 bp, and its members were assembled by 4 to 9 oligos. (Figure 8B). Six amplicons / clones per construct were amplified from colonies using barcoded vector primers (312 amplicons total), pooled, and nanopore sequenced. In this experiment, 95% of the constructs were correctly assembled, 70% of the clones sequenced were error-free, and at least one error-free clone was obtained for all 52 targets (Figure 8B). We additionally tested assemblies of larger (-3100 bp) sequences harboring a central GFP expression cassette. The three -3100 bp constructs were designed with distinct assembly overhangs, synthesized as oligonucleotides, amplified and assembled; representative colony plates displayed 53%, 8%, and 43% assembly efficiencies for the three constructs. (Figure 8C). Thus, iggypop should enable the routine assembly of up to 18 fragments; however, we developed a two-step assembly process to minimize the amount of amplicon sequencing required for isolating longer error-free constructs.

[0527] Example 2: Construction of single transcript bioluminescence reporters

[0528] Having established the iggypop pipeline, we used it to design plant reporter constructs, focusing on a fungal bioluminescence pathway (13-16) that enables autonomous gene expression reporting. Since the discovery of the complete five-gene pathway, multiple improvements have been made (15), but the complexity and size of the five transcription unit T-DNA make it challenging to work with; it additionally contains repeated sequence elements that can be problematic. To address these issues, we tested if we could build a single-transcript autonomous bioluminescence reporter system (STARBURST) by linking the pathway’s five enzymes together with intervening LP4 / 2A ribosomal skipping peptides (17-19). We designed and synthesized constructs with three different gene orders in a two-step process (Figure 9B)Attorney Docket No.: 690104.0045

[0529] (SEQ ID NOS: 1-5). A target sequence was divided into small segments at junctions predicted to assemble with high-fidelity; the segments were flanked BsmBI sites, which were used for the second step assembly. The fragments were then synthesized separately from oligonucleotide pools, with each oligo flanked by BbsI sites, which were used for the first-step assembly reactions. (Figure 9A). The -9.5 kb coding sequences were broken into nine -1050 bp segments at junctions yielding high-fidelity assembly overhangs; these “step-one” blocks were synthesized separately from oligonucleotide pools, sequence validated, and then assembled in a second step to yield the final targets. (Figure 9A).

[0530] Using this approach, we created multiple Arabidopsis codon-usage-matched versions of designs that place the longest gene (HispS; -5 kb) in the first or second positions (Figure 9B) (Nucleotide sequences: SEQ ID NOS: 1-4). The constructs link the five genes of the fungal bioluminescence pathway with LP4 / 2A ribosomal skipping peptides. Three different gene orders were used among the variants designed and synthesized. (SEQ ID NOS: 1-5). Two different Arabidopsis codon-matched variants were created for the first two designs (SEQ ID NOS: 1-4), and a single codon-optimized sequence was used for the third design (SEQ ID NO: 5) (Figure 9B).

[0531] As a control, we additionally synthesized a published 15.3 kb optimized Neonothopanus nambi expression cassette harboring the five enzymes as separate transcription units (Figure 9C) (15). The cassette expresses the same protein products (i.e., wild-type or mutant variants) (SEQ ID NOS: 237-241) used in the design of the single transcript constructs. (Figure 9C).

[0532] Clones 1 -5 (SEQ ID NOS: 1-5) and the A. nambi control were transiently expressed in N. benthamiana leaves. Luminescence was observed in all five clones, with clones 3 and 4 (the single transcript designs with hispidin synthase (HispS) as the first coding sequence [SEQ ID NOS: 3 and 4]) were the brightest (Figure 9D). The images shown were acquired 4 days after co-infiltration with pl9. (Figure 9D). Plants harboring a 35S-driven construct for clone #3 produced luminescence in transgenic Arabidopsis and N. benthamiana, indicating function in stable transgenic plants. (Figure 9E and Figure 10). 35S-driven STARBURST (corresponding to clone #3 from Figure 8B) was constructed using Goldenbraid assembly into a pC AMBIA backbone, yielding the final T-DNA shown (Figure 10). The construct was introduced into Arabidopsis by floral dip transformation and multiple T1 lines isolated.

[0533] Attorney Docket No.: 690104.0045

[0534] A 35S-driven STARBURST (corresponding to clone #3 from Figure 9B) was constructed using Goldenbraid assembly into a pCAMBIA backbone, yielding the final T-DNA shown in Figure 10. The construct was introduced into Arabidopsis by floral dip transformation and multiple T1 lines isolated. The brightest of several lines is shown in Figure 10.

[0535] Example 3: Effect of GC content and predicted splice junction elimination on synthetic gene expression

[0536] The expression of coding sequences moved between organisms can be low due to inappropriately spliced cryptic introns, as illustrated by the original attempts to express A. victorialis GFP in plants (20). We believed that synthetic coding sequences, particularly long ones, could benefit from removing potential intronic sequences predicted using machine learning models (21). We incorporated a function into iggypop to identify and replace predicted intron acceptor and donor sites with synonymous mutations. We used the 4.2 kb RUBY reporter gene as a test case for this approach and synthesized six ^zzz / ?zt / / zsz.s-codon-matched sequences, of which three were purged of predicted junctions, as well as a control RUBY sequence, and tested them in transient N. benthamiana assays (Figure 11 A). These experiments did not suggest a benefit of eliminating predicted splice junctions, at least for our small set of RUBY test sequences; however, we surprisingly observed that all of the designed sequences produced between 5.5 to 18-fold less pigment than the RUBY control, suggesting that our design process, which had matched Arabidopsis codon usage for all test clones, had reduced their effectiveness (Figure 1 IB). Quantification of pigmentation levels for RUBY and codon-matched variants shown were conducted after ethanol extraction of leaf discs as described in reference (29).

[0537] Inspection of RUBY’s sequence indicated that its GC content is much higher than our designed sequences - 58% GC content for RUBY and 44 - 45% for our designed sequences (Figure 11 A). Predicted splice junctions were purged from three of the six designs (vl - v3); all six designs match Arabidopsis codon usage. Images were acquired 2 days post infiltration; infiltrations were conducted using pl9 co-infiltrations. (Figure 11 A).

[0538] RUBY’s three enzymes originated from the dicotyledonous plant Beta vulgaris and possess similar GC and GCss content Arabidopsis genes (Figure 12); however, we eventually learned that RUBY’s sequence was designed to match rice GC-rich codon usage (52) and has a low codon adaptation index (CAI) for N. benthamiana despite its highly efficient expression in

[0539] Attorney Docket No.: 690104.0045

[0540] eudicots (Figure 12).

[0541] We designed and synthesized six new bioluminescence clones with GC contents spanning 53% to 63% (SEQ ID NOS: 7-12) and compared these to an dra / vc / o / zs / .s-codon-matched sequence, which has -48% GC content. Remarkably, all of the GC -boosted clones showed -16- fold increases in luminescence in transient. V. benthamiana assays relative to the original clones that encode the same polypeptide (Figure 11C). Three leaf punches per spot (n = 7 or greater leaves) were collected, and luminescence was measured using a Tecan Spark spectrophotometer. GC -boosted STARBURSTs (SEQ ID NOS: 7-12) produce high-level luminescence in N. benthamiana transient assays. Luminescence in transient N. benthamia assays of the six bioluminescence clones (coding sequence for design #2) and clone 4 with 48% GC content (SEQ ID NO: 4) was measured using a Tecan Spark spectrophotometer. (Figure 11D). GC- boosted STARBURSTs produce high-level luminescence in N. benthamiana transient assays. (Figures 11C and 11D). The six GC -Boosted STARBURSTs were designed using iggypop with varying GC contents (all designs were also “deintronized”).

[0542] The pPlant-POP-STARBURST (53% GC) clone (SEQ ID NO. 7) was introduced into Arabidopsis by floral dip transformation and multiple T1 lines isolated. One of >10 bioluminescent lines obtained is shown (Figure 13).

[0543] This experiment demonstrates that synthetic plant gene design can benefit from testing designs with elevated GC content.

[0544] Example 4: Mutagenesis o Neonothopanus nambi luciferase (nnLuz) and Transient Expression of Luciferase mutant clones in N. benthamiana leaves

[0545] In previous studies, mutagenesis of Neonothopanus nambi luciferase (nnLuz) identified a nonuple mutant called nnLuzv4 with increased brightness relative to wildtype nnLuz (SEQ ID NO. 280). (Shakhova et al. 2024). nnLuzv4 was created by random mutagenesis and targeted mutations that convert four sites to harbor consensus residues (i.e., the most frequent amino acid from multiple sequence alignments of fungal luciferases). We defined 32 sites in nnLuzv4 for combinatorial mutagenesis to generate further variants with new properties. We created 16 new mutant sequences (Nucleotide sequences: SEQ ID NOS: 13-28; Amino acid sequences: SEQ ID NOS: 247-262) derived from nnLuzv4 (Nucleotide sequence: SEQ ID NO. 245; Amino acid sequence: SEQ ID NO: 240) by randomly substituting between 13 to 18 mutations from the

[0546] Attorney Docket No.: 690104.0045

[0547] following list of candidates: S6N, G27V, V29A, A35L, I38Y, E48S, R59K, I62L, S68A, D81E, E97N, P99T, T113N, Q114V, L115A, V116P, D117V, Q118P, E119D, I161V, L167K, I169V, C191F, G202A, L206V, K207S, L231I, A240L, R241A, V247I, I262V, V263I. The candidates were selected based on manual inspection of multiple sequence alignments to define variable sites that could be harnessed to introduce conservative variants to improve stability, activity, or other properties. The sequences were synthesized along with nnLuzv4 (SEQ ID NO: 245) from oligonucleotide pools using iggypop and cloned into pPlant-Pop to yield a series of luciferases expressed from a UBQ10 promoter. In addition, a two-step protocol was used to synthesize a STARBURST derivative devoid of luciferase and its terminal GSG-LP4 / 2A linker but otherwise identical to STARBURST clone #3 (STARBURST3-noLUZ) (SEQ ID NO: 233). The 16 luciferase clones (Nucleotide sequences: SEQ ID NOS: 13-28), nnLuzv4 control (Nucleotide sequence SEQ ID NO: 245; amino acid sequence: SEQ ID NO: 240), and STARBURST3-noLUZ control (STARBURST clone #3 construct with the nnLUZv4 gene removed) (Nucleotide sequence SEQ ID NO: 233) were transformed into agrobacterium, and agrobacteria strains harboring mutant or control luciferases were co-infdtrated with an agrobacterium strain harboring STARBURST3-noLUZ (SEQ ID NO: 233) and a third strain harboring pl9.

[0548] Luminescence was observed for all clones; mutants 3 (SEQ ID NOS: 15 and 249) and 6 (SEQ ID NOS: 18 and 252) showed improvements relative to the nnLuzv4 controls (SEQ ID NOS: 240 and 245) included on their corresponding leaves. (Figure: 14) Since nnLuzv4 (SEQ ID NO: 240 and 245) has improved luminescence relative to wild-type nnLuz (SEQ ID NO: 280) (Shakhova el al. 2024), the new variants, except mutants 7 and 14 (Nucleotide sequences: SEQ ID NOS: 19 and 29; Amino Acid sequences: SEQ ID NOS: 253 and 260) are improved relative to wild-type nnLuz (SEQ ID NO: 280). (Figure: 14).

[0549] Identified below are the specific nnLuzv4 enhancing mutations in Mutant 3 (SEQ ID NO: 249), and Mutant 6 (SEQ ID NO. 252) relative to nnLuzv4 (SEQ ID NO: 240):

[0550] Mutant 3: G27V, A35L, I62L, S68A, D81E, E97N, V116P, Q118P, I169V, C191F, G202A, K207S, A240L, V263I

[0551] Mutant 6: S6N, 138 Y, I62L, S68A, E97N, P99T, LI 15 A, Il 6 IV, L167K, 1169V, L231I,

[0552] A240L, R241A

[0553] Attorney Docket No.: 690104.0045

[0554] Example 5: Mutagenesis of Neonothopamis nambi hispidin-3-hydroxylase (nnH3H)

[0555] In previous studies, mutagenesis of Neonothopamis nambi hispidin-3-hydroxylase (nnH3H) identified a quadruple mutant called nnH3Hv2 (Nucleotide sequence: SEQ ID NO. 244; Amino acid sequence: SEQ ID NO. 239) that yielded increased luminescence relative to wild-type nnH3H (SEQ ID NO. 279) when expressed along with other factors required for autonomous bioluminescence (Shakhova etal. 2024). NnH3Hv2 (Nucleotide sequence: SEQ ID NO. 244; Amino acid sequence: SEQ ID NO. 239) was created by combinatorial mutagenesis that converted four amino acids to harbor consensus residues (z.e., the most frequent amino acid from multiple sequence alignments of fungal luciferases). We defined a set of sites in nnH3Hv2 for combinatorial mutagenesis to generate variants with new properties. We created 16 mutant sequences (nucleotide sequences: SEQ ID NOS: 45-60; amino acid sequences: SEQ ID NOS: 263-278) derived from nnH3Hv2 by randomly substituting amino acids based on manual inspection of multiple sequence alignments to define variable sites that could be harnessed to engineer improved stability, activity, or other properties. The sequences were synthesized along with nnH3Hv2 from oligonucleotide pools using iggypop and cloned into pPlant-Pop to yield a series of H3H mutants expressed from a UBQ10 promoter. In addition, a two-step protocol was used to synthesize a STARBURST derivative devoid of nnH3Hv2 and its terminal GSG-LP4 / 2A linker but otherwise identical to STARBURST clone #3 (STARBURST3-noH3H) (SEQ ID NO: 234). The 16 nnH3Hv2 mutant clones (nucleotide sequences: SEQ ID NOS: 45-60), nnH3Hv2 control (SEQ ID NO: 244), and STARBURST3-noH3H control (STARBURST clone #3 construct with the nnH3Hv2 gene removed) (Nucleotide sequence SEQ ID NO: 234) were transformed into agrobacterium, and agrobacteria strains harboring mutant or control luciferases were co-infiltrated with an agrobacterium strain harboring STARBURST3-noH3Hv2 (SEQ ID NO: 234) and a third strain harboring pl9. Luminescence was observed for most clones; mutants 1 (SEQ ID NOS: 45 and 263), 4 (SEQ ID NOS: 48 and 266), 7 (SEQ ID NOS: 51 and 269), 13 (SEQ ID NOS: 57 and 275), and 14 (SEQ ID NOS: 58 and 276) showed substantial improvements relative to the nnH3Hv2 controls (SEQ ID NOS: 239 and 244) included on their corresponding leaves; of these, mutant 7 (SEQ ID NOS: 51 and 269) yielded the greatest improvement in bioluminescence relative to nnH3Hv2 (Nucleotide sequence: SEQ ID NO. 244; Amino acid sequence: SEQ ID NO. 239).

[0556] Identified below are the specific nnH3Hv2 enhancing mutations in Mutant 1 (SEQ ID

[0557] Attorney Docket No.: 690104.0045

[0558] NO: 263), Mutant 4 (SEQ ID NO. 266), Mutant 7 (SEQ ID NO. 269), Mutant 13 (SEQ ID NO: 275), and Mutant 14 (SEQ ID NO: 276) relative to nnH3Hv2 (SEQ ID NO: 239):

[0559] Mutant 1 (SEQ ID NO. 263): A43T, S58C, Q60L, T66I, G81A, S102P, M116R, V118L, T138V, F139S, V147I, V161I, E176G, V187A, T220A, R233H, A251G, N260D, A262V, D263A, A268V, S269T, R285K, Q292D, M323S, D367E, S408A

[0560] Mutant 4 (SEQ ID NO. 266): A43T, S58C, Q60L, Q61G, T66I, G71P, A79R, S102P, M116R, T138V, V147I, V161I, E176G, K210N, T220A, N260D, D263A, S265N, A268V, K270Q, R285K, M323S, E379Q

[0561] Mutant 7 (SEQ ID NO. 269): A43T, S58C, Q60L, T66I, G71P, G81A, S102P, F139S, V161I, E176G, V187A, K210N, T220A, A251G, T261S, D263A, S265N, S269T, K270Q, R285K, M323S, D367E, L395M

[0562] Mutant 13 (SEQ ID NO. 275): A43T, S58C, Q60L, Q61G, G71P, A79R, S102P, M116R, V118L, F139S, V147I, V161I, E176G, V187A, K210N, A251G, A262V, D263A, R285K, Q292D, M323S, E379Q, L395M, S408A

[0563] Mutant 14 (SEQ ID NO. 276): A43T, Q61G, T66I, G71P, S102P, M116R, F139S, V147I, V161I, E176G, V187A, K210N, R233H, A251G, N260D, T261S, D263A, S265N, A268V, S269T, Q292D, D367E, E379Q, S408A

[0564] Methods used in examples

[0565] Sequence domestication and codon optimization

[0566] iggypop includes pipelines for processing fasta and Genbank formatted sequences into oligonucleotide pools; the fragments for each target gene are amplified with a unique primer pair and assembled using Golden Gate methods. It uses dnachisel (30), a Python library of sequence optimization functions, to optimize and domesticate sequences. Codon optimization uses either Kazusa or the more current CoCoPUTs dataset of codon tables (31). All sequences were designed using UniquifyAllKmers optimization parameter to prevent sequence repeats of 12 or greater nucleotides, AvoidHairpins constraint to preclude hairpins of 20 nucleotide or greater over a 250 bp window, and AvoidPattern constraints to preclude common IIS restriction site sequences. Iggypop uses YAML files to specify dnachisel parameters used for sequence optimizations, iggypop installation and usage information is provided in the iggypop GitHub repository (https: / / github.com / cutlersr / iggypop).

[0567] Attorney Docket No.: 690104.0045

[0568] High-fidelity overhang sets

[0569] High-fidelity overhang sets are used to improve multi-fragment Golden Gate ligations. We achieved this by selecting hinge overhangs from precomputed high-fidelity sets (hingesets)', which are used to constrain overhang selections by goldenhinges — a Python package that fragments sequences at junctions that produce unique hinge sets within a specified radius of targeted cut sites (32). The predicted ligation fidelities of hinging solutions generated using this approach are as good or better than the fidelity of the constraining set from which the solution is selected. We created our hingesets using a genetic algorithm optimizer to create high-fidelity sets of varying sizes scoring fidelities using Potapov et al. (12) data; all sets included 5’-AATG-3’ and 5’-GCTT-3’, which are used for cloning into pPOP vectors. We note that AATG & GCTT have a near-perfect predicted ligation fidelity and are compatible with GoldenBraid 2.0 and MoClo coding sequence rules (33). When tested against

[0570]

[0571] cDNAs, hingesets produced a predicted median fidelity of 99.8% (Figure 16). A collection of ~10K transcription factor coding sequences for citrus, hemp, beet, and papaya was collated from TfDB (51). The overhang set sizes, the number of fragments required for assembly from 250 bp oligos, predicted ligation fidelities for the set, and summary statistics are shown. Predicted ligation fidelities were calculated as described in reference (12) using a data set for T4 DNA ligase and Bsal at 25 °C for 18 hours.

[0572] Indexing primers

[0573] To create indexing primers, we randomly generated 50% GC, restriction-siteless sequences as primer 3-py (34) templates, with its parameters set to generate 18-mers with 60 °C Tm. We sought to filter these then to create a final set of primers with (i) reduced potential to cross-hybridize to other index primers and (ii) reduced potential to amplify common lab contaminant DNAs. To do this, we scored a set of ~1M index primer candidates for the formation of amplicons or hybridization to contaminant DNAs using MF Eprimer- 3 (35) and used MFEPrimer3s ’ thermodynamics-based calculations to remove primers with hairpins or pairs that formed dimers. The remaining -700K primers were then scored for pairwise cross-hybridization using MF EPrimer 3, and the 10K primers with the lowest cross-hybridization scores (indexset) were retained.

[0574] pPOP vectors

[0575] Attorney Docket No.: 690104.0045

[0576] The pPOP vectors produce 5’-AATG-3’- and 5’-GCTT-3’-compatible overhangs when digested with either BsmBI or BbsI; these were created by modifying pUPD2 (36) to add cloning sites and an intervening AmilCP E. coli expression cassette to enable blue / white insert screening (derived from mUAV (37)). These vectors were built using PCR and Golden Gate cloning. pPlantPOP was designed similarly but with a pCAMBIA backbone to allow for one-step assembly and subsequent functional analyses in planta. pPlantPOP contains an AtUbql0p: BsmBI-AmilCP-BsmBI: E9-terminator cloning cassette and NOSp: NPTII & 35Sp-DsRed selection / reporter cassettes. The pPOP vectors were confirmed by whole-plasmid sequencing (Aventis Life Sciences, USA) and have been deposited at Addgene (USA).

[0577] Gene assembly

[0578] Oligonucleotide pool templates were synthesized by Twist Bioscience (USA), resuspended to 1 ng / pL in sterile ddH^O, and used in PCR reactions using Phusion High-Fidelity DNA Polymerase (New England Biolabs, USA) in 25 pL reactions with 4 pg template, 1 pM each index primer, 200 pM dNTPs, and lx HF buffer. PCR was performed using an initial denaturation at 98°C (30s), followed by 30 cycles of 98°C (10s), 60°C (30s), and 72°C (30s). The PCR products were purified using Sera-Mag SpeedBeads (Cytiva) or MagMAX Pure Bind Beads (ThermoFisher Scientific, USA). MagMAX -Bead purifications were conducted according to the manufacturer's protocol, using 40 pL of bead suspension per PCR reaction; the purified fragments were eluted in 15 pL sterile ddH2O and quantified using a Nanodrop Spectrophotometer (ThermoFisher, USA), with recoveries typically yielding 10 - 40 ng / pl. Sera-Mag SpeedBead purifications were conducted according to a literature protocol (38), using 50 pL of bead suspension per 25 pL PCR reaction; the purified fragments were eluted in 25 pL sterile 10 mM Tris-HCl (pH 8.0) prewarmed to 50°C with recoveries of ~10 - 20 ng / pl.

[0579] The purified fragments were assembled in reactions using 35 ng pPOP -BsmBI or 60 ng pPlantPOP, using ~5.5 ng per fragment (i.e., 33 ng of a purified pool with six fragments) in 10 pL reactions using aNEBridge BsmBI-v2 master mix (New England Biolabs, USA) according to the manufacturer's protocol. The reactions were run in a thermal cycler for 90 cycles at 42 °C, then 16 °C, and final inactivation at 60 °C for 5 mins. Transformations were conducted in 96-well thin-walled PCR plates in a thermal cycler. 2 pl of each ligation was added to 50 pL chemically competent homemade ToplO E.coli cells, incubated on ice for 30 minutes, heat-shocked in the thermal cycler at 42 °C (60 s), and transferred to ice for 5 minutes. Each transformation was thenAttorney Docket No.: 690104.0045

[0580] transferred to a deep 96-well plate into 250 pL SOC and incubated with shaking (200 rpm) for 1 hour (37 °C), then plated onto either 6-well or 9 cm LB + chloramphenicol (25 mg / L) Petri plates.

[0581] Amplicon barcode design

[0582] We used custom barcoded primer pairs to colony PCR of candidates from pPOP vectors and sequenced the amplicons using Oxford Nanopore Technology (Oxford, UK). To enable this, we designed a set of 96 18-mer primer barcodes with a minimal edit distance of 8 (average -10); we appended these to forward and reverse primer pairs flanking pPOP coning sites, synthesized them (IDT, USA), and used them in colony PCRs. The barcodes were generated using iggypop.py primers to create a set of candidate 18-mer primers, which were processed to identify a maximally different subset using barcode selection.py, available in the iggypop repository. Nanopore amplicon sequencing

[0583] We PCR amplified assemblies from colonies using GoTaq DNA Polymerase (Promega, USA) in 10 pl reactions with 0.1 pM each barcoded primer. 2 pL of each reaction was combined into a pool, bead-purified using an equal volume of MagMAX or 2X volume of Ser-Mag beads. The barcoded amplicons were resuspended to a final concentration of -100 - 500 ng / uL; 1.5 pg of the pooled products were then repaired using NEBNext (New England Biolabs, USA), purified using an equal volume of MagMAX and ligated to adapters using the Ligation Sequencing Kit XL V14 (Oxford Nanopore Technologies, USA), purified and quantified using a Qubit. 50 fmol (-60 ng) was then analyzed using a MinION Flow Cell R10.4.1 (Oxford Nanopore Technologies, USA). The data obtained was processed using iggyseq.sh, which uses MiniBar (39) to demultiplex reads, chopper (40) to remove low-quality reads, minimap2 (41) to map reads to reference sequences, and samtools (42), bcftools (42), bedtools (43), racon (44), medaka (45), seqtk (46), emboss (47), and parallel (48) to generate consensus sequences, annotate variants, and output summaries. The iggyseq.sh amplicon sequence analysis pipeline is available at Zenan’s Github repository.

[0584] sfGFP control assemblies

[0585] An ~1000-bp expression cassette composed of super folder GFP (sfGFP), the strong J23119 promoter, B0034 ribosome binding site, and rrnB Tl / lambda tO terminators was designed in Geneious; this central sequence was fixed, and three derivatives designed, flanked on each side by -1 kb of randomly generated, 50% GC, restriction-siteless sequence. The three sequencesAttorney Docket No.: 690104.0045

[0586] were fragmented using iggypop into 18 oligonucleotides. Each of the three fragment sets uses different overhang / hinge sets due to the non-identical arms flanking the sfGFP casette. The oligonucleotide fragments were synthesized by Twist (USA) and assembled as described above. Assembly efficiencies were established by counting the number of GFP+colonies obtained relative to the total number of amilCP colonies. Six clones per assembly were analyzed by PCR to confirm the correct insert sizes.

[0587] Deintronization and GC-tuning

[0588] The sequences were optimized to match Arabidopsis codon usage in combination with a “deintronization” protocol designed to iteratively mutate sequences of potential intron junctions predicted by using a 200 bp window and spliceator (21) using dnachisels’ AvoidPattern function to introduce synonymous mutations in up to 4 iterations of intron scanning and synonymous mutation. Acceptor / donor-free clones were selected from multiple runs, if not obtained on the first pass. GC content was tuned using dnachisels ’ optimization parameters; a minimum specified GC content over a 60-base pair sliding window was used with match codon usage to an Arabidopsis codon table. A 4x multiplier (boost) was applied to the GC-content scoring function to ensure that GC content dominated the optimization relative to codon usage. RUBY sequences were designed to use match codon usage and an Arabidopsis codon table; three of the six designed sequences used the deintronization option described above.

[0589] Two-step assemblies

[0590] Sequences were designed to be assembled in a two-step process. First, target sequences are modified to add Bsal sites with AATG / GCTT overhangs adjacent to the start and stop codons, yielding domesticated, GoldenBraid, and MoClo compatible level 0 / level-a coding sequences (i.e. they generate 5’-AATG... GCTT-3’ hinges after Bsal digestion) that could be cloned into pPOP vectors. These were then broken into -1000 base pair segments at junctions identified to produce high-fidelity overhangs and terminal BsmBI sites appended to yield “step-one” fragments; each fragment was then synthesized from oligonucleotides flanked by BbsI sites; PCR amplified products were assembled using four units of BbsI-HF (New England Biolabs, USA), 200 units of T4 DNA ligase (New England Biolabs, USA) in 1x T4 DNA ligase buffer, and assemblies cloned into pPOP-BbsI. After sequence validation, the step-one fragments were assembled using 0.5 nM of each of the step-one plasmids (~30 ng) in a 15 pl reaction mixAttorney Docket No.: 690104.0045

[0591] with NEBridge (BsmBl-v2) enzyme mix and 90 ng of the pPlantPOP vector; the final clones were confirmed by whole plasmid sequencing (Azenta Life Sciences, USA).

[0592] Nn control cassette

[0593] As a positive control, we also synthesized a 15.3 kb sequence identical to an optimized 5-gene pathway described by Shakhova et al. (15). The sequence from pNK6541 encompassing a p35S-mcitHispS-tOCS through to pCmYLCV-npgA -tATP was extracted and iggypop used to fragment the sequence into nine -1500 bp step-one fragments, which were assembled from oligonucleotide pools, as described above, into pPOP-BbsI for the first step, and pPlantPOP for the second step and whole-plasmid sequence validated.

[0594] Transient assays of RUBY and STARBURST function

[0595] We conducted transient assays in N. benthamiana using the AGROBEST protocol (49). N. benthamiana were grown in 16-hour days, and leaves from 4 - 5 week-old plants infiltrated with Agrobacteria C58 harboring pPlantPOP-STARBURST or pPlantPOP -RUB Ycl ones along with strains expressing pl9, with each strain present at 0.3 ODeoo units in AGROBEST media (49). The luminescence images were acquired three or four days after infiltration using a Sony A7S (ILCE-7S, FE 90mm F2.8 Macro G OSS lens) at ft aperture, 30s exposure, and 6400 ISO. The RUBY images shown were acquired 2 days after infiltration. Betalains were extracted from leaf discs in 50% EtOH; the absorbance of 100 pl of the solution was measured at A538 in a transparent flat bottom 96 well plate using Tecan Spark. Pigment amounts were inferred according to reference (29). Leaf disc luminescence values were measured using a Tecan Spark.

[0596] Transgenic plants

[0597] Arabidopsis and N. benthamiana transgenic plants were constructed using 35Sp-STARBURST (clone #3). Arabidopsis transformations were conducted using the floral dip method (50). Transgenic N. benthamiana cotyledons were infected with Agrobacterium (C58) resuspended in AGROBEST acetosyringone (100 pM) ODeoo =0.3 with for 15 minutes, transferred to co-cultivation media (1x MS, 2.5% sucrose, 0.8% agar, 100 pM acetosyringone) in darkness for 2 days. They were subsequently transferred to regeneration plates (1X MS, 2.5% sucrose, 0.8% agar, 1 mg / L benzylaminopurine, 0.1 mg / L 1 -Naphthaleneacetic acid, 300 mg / L cefotaxime), after which they were transferred to fresh media every 10 days. Transgenic shoots were identified by DsRed fluorescence and rooted on tissue culture media (1x MS, 2.5% sucrose,Attorney Docket No.: 690104.0045

[0598] 0.8% agar, 300 mg / 1 cefotaxime) and then transferred to the soil and cultivated under 16-hour days.

[0599] References;

[0600] 1. S. Kosuri, G. M. Church, Large-scale de novo DNA synthesis: technologies and applications. Nature Methods 11, 499-507 (2014).

[0601] 2. A. Frary, C. M. Hamilton, Efficiency and Stability of High Molecular Weight DNA Transformation: an Analysis in Tomato. Transgenic Res. 10, 121-132 (2001).

[0602] 3. Y.-M. Cai, et al.. Rational design of minimal synthetic promoters for plants. Nucleic Acids Res 4, 11845-11856 (2020).

[0603] 4. T. Jores, et al., Synthetic promoter designs enabled by a comprehensive analysis of plant core promoters. Nat Plants 7, 842-855 (2021).

[0604] 5. G. A. Luke, M. D. Ryan, “The 2A story: The end of the beginning” in Genetics, (IntechOpen, 2024).

[0605] 6. P. de Felipe, et al., E unum pluribus: multiple proteins from a self-processing polyprotein. Trends Biotechnol 24, 68-75 (2006).

[0606] 7. 2A-linked bi-, tri-, and quad-cistrons for the stepwise biosynthesis of 0-carotene, zeaxanthin, and ketocarotenoids in rice endosperm. Metabolic Engineering Communications 12, e00166 (2021).

[0607] 8. X. Liu, et al.. Engineering of “Purple Embryo Maize” with a multigene expression system derived from a bidirectional promoter and self-cleaving 2A peptides. Plant Biotechnology’ Journal 16, 1107-1109 (2018).

[0608] 9. M. Geier, P. Fauland, T. Vogl, A. Glieder, Compact multi-enzyme pathways in P. pastoris. Chem Commun (Camb) 51, 1643-1646 (2015).

[0609] 10. S. Lund, V. Potapov, S. R. Johnson, J. Buss, N. A. Tanner, Highly Parallelized Construction of DNA from Low-Cost Oligonucleotide Mixtures Using Data-Optimized Assembly Design and Golden Gate. ACS Synth Biol 13, 745-751 (2024).

[0610] 11. A. Hossain, D. P. Cetnar, T. L. LaFleur, J. R. McLellan, H. M. Salis, Automated Design of Oligopools and Rapid Analysis of Massively Parallel Barcoded Measurements. ACS Synth Biol 13, 4218-4232 (2024).

[0611] 12. V. Potapov, etal., Comprehensive Profiling of Four Base Overhang Ligation Fidelity byAttorney Docket No.: 690104.0045

[0612] T4 DNA Ligase and Application to DNA Assembly. ACS Synth Biol 7, 2665-2674 (2018).

[0613] 13. T. Mitiouchkina, et al., Plants with genetically encoded autoluminescence. Nat.

[0614] Biotechnol. 38, 944-946 (2020).

[0615] 14. A. A. Kotlobay, et al., Genetically encodable bioluminescent system from fungi. Proc. Natl. Acad. Sci. U. S. A. 115, 12728-12732 (2018).

[0616] 15. E. S. Shakhova, et al., An improved pathway for autonomous bioluminescence imaging in eukaryotes. Nat Methods 21, 406-410 (2024).

[0617] 16. A. Khakhar, et al.. Building customizable auto-luminescent luciferase-based reporters in plants. Elife 9, e52786 (2020).

[0618] 17. I. E. J. A. Francois, et al., Transgenic expression in Arabidopsis of a polyprotein construct leading to production of two different antimicrobial proteins. Plant Physiol 128, 1346— 1358 (2002).

[0619] 18. I. E. J. A. Francois, et al., Processing in Arabidopsis thaliana of a heterologous polyprotein resulting in differential targeting of the individual plant defensins. Plant Sci. 166, 113-121 (2004).

[0620] 19. H. Sun, N. Zhou, H. Wang, D. Huang, Z. Lang, Processing and targeting of proteins derived from polyprotein with 2A and LP4 / 2A as peptide linkers in a maize expression system. PLoSOne 12, e0174804 (2017).

[0621] 20. J. Haseloff, K. R. Siemering, D. C. Prasher, S. Hodge, Removal of a cryptic intron and subcellular localization of green fluorescent protein are required to mark transgenic Arabidopsis plants brightly. Proc Natl Acad Sci U S A 94, 2122-2127 (1997).

[0622] 21. N. Scalzitti, et al., Spliceator: multi-species splice site prediction using convolutional neural networks. BMC Bioinformatics 22, 561 (2021).

[0623] 22. G. Kudla, L. Lipinski, F. Caffin, A. Helwak, M. Zylicz, High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol 4, e180 (2006).

[0624] 23. J. Fu, Y. Dang, C. Counter, Y. Liu, Codon usage regulates human KRAS expression at both transcriptional and translational levels. J Biol Chem 293, 17929-17940 (2018).

[0625] 24. C. Mordstein, et al., Codon Usage and Splicing Jointly Influence mRNA Localization. Cell Syst 10, 351-362.e8 (2020).

[0626] 25. M. Courel, et al., GC content shapes mRNA storage and decay in human cells. Elife 8 (2019).

[0627] Attorney Docket No.: 690104.0045

[0628] 26. Z. Zhou, et aL, Codon usage is an important determinant of gene expression levels largely through its effects on transcription. Proc Natl Acad Sci USA 113, E6117-E6125 (2016).

[0629] 27. L. V. Sidorenko, etal., GC-rich coding sequences reduce transposon-like, small RNA-mediated transgene silencing. Nature Plants 3, 875-884 (2017).

[0630] 28. F. Hia, et al., Codon bias confers stability to human mRNAs. EMBO Rep 20, e48220 (2019).

[0631] 29. D. Pramanik, K. Lee, K. Wang, A simple and efficient method for betalain quantification in -expressing plant samples. Front Plant Sci 15, 1449409 (2024).

[0632] 30. V. Zulkower, S. Rosser, DNA Chisel, a versatile sequence optimizer. Bioinformatics 36, 4508-4509 (2020).

[0633] 31. A. Alexaki, et al., Codon and Codon-Pair Usage Tables (CoCoPUTs): Facilitating Genetic Variation Analyses and Recombinant Gene Design. J Mol Biol 431, 2434-2441 (2019).

[0634] 32. GoldenHinges: Short overhangs design for DNA assembly. GitHub. Available at: https: / / github.com / Edinburgh-Genome-Foundry / GoldenHinges [Accessed 27 October 2024],

[0635] 33. A. Sarrion-Perdigones, et al., GoldenBraid: An Iterative Cloning System for Standardized Assembly of Reusable Genetic Modules. PLoS One 6, e21622 (2011).

[0636] 34. primer3-py: simple oligo analysis and primer design. GitHub. Available at: https: / / github.com / libnano / primer3-py [Accessed 27 October 2024],

[0637] 35. K. Wang, et al., MFEprimer-3.0: quality control for PCR primers. Nucleic Acids Res 47, W610-W613 (2019).

[0638] 36. A. Sarrion-Perdigones, et al., GoldenBraid 2.0: A Comprehensive DNA Assembly Framework for Plant Synthetic Biology. Plant Physiol. 162, 1618-1631 (2013).

[0639] 37. A. I. Andreou, N. Nakayama, Mobius Assembly: A versatile Golden-Gate framework towards universal DNA assembly. PLoS One 13, e0189892 (2018).

[0640] 38. J. B. Ridenour, R. Donczew, A method to prepare Sera-Mag SpeedBeads for purification and size selection of nucleic acids v2. (2024).

[0641] 39. H. Krehenwinkel, et al., Nanopore sequencing of long ribosomal DNA amplicons enables portable and simple biodiversity assessments with high phylogenetic resolution across broad taxonomic scale. Gigascience 8, giz006 (2019).

[0642] 40. W. De Coster, R. Rademakers, NanoPack2: population-scale evaluation of long-read sequencing data. Bioinformatics 39, btad311 (2023).

[0643] Attorney Docket No.: 690104.0045

[0644] 41. H. Li, Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 34, 3094-3100 (2018).

[0645] 42. P. Danecek, et al., Twelve years of SAMtools and BCFtools. Gigascience 10 (2021).

[0646] 43. A. R. Quinlan, I. M. Hall, BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841-842 (2010).

[0647] 44. R. Vaser, I. Sovic, N. Nagarajan, M. Sikic, Fast and accurate de novo genome assembly from long uncorrected reads. Genome Res. 27, 737-746 (2017).

[0648] 45. medaka: Sequence correction provided by ONT Research. GitHub. Available at: https: / / github.com / nanoporetech / medaka [Accessed 27 October 2024],

[0649] 46. W. Shen, B. Sipos, L. Zhao, SeqKit2: A Swiss army knife for sequence and alignment processing. Imeta 3, el91 (2024).

[0650] 47. P. Rice, I. Longden, A. Bleasby, EMBOSS: The European molecular biology open software suite. Trends Genet. 16, 276-277 (2000).

[0651] 48. O. Tange, GNU Parallel 20220122 (’20 years') (Zenodo, 2021).

[0652] 49. H.-Y. Wu, et al., AGROBEST: an efficient Agrobacterium-mediated transient expression method for versatile gene function analyses in Arabidopsis seedlings. Plant Methods 10, 19 (2014).

[0653] 50. S. J. Clough, A. F. Bent, Floral dip: a simplified method forAgrobacterium-mediated transformation of Arabidopsis thaliana. Plant J. 16, 735-743 (1998).

[0654] 51. J. Jin, et al., PlantTFDB 4.0: toward a central hub for transcription factors and regulatory interactions in plants. Nucleic Acids Res 45, D1040-D1045 (2017).

[0655] 52. Y. He, et al., A reporter for noninvasively monitoring gene expression and plant transformation. Horticulture Research. Vol. 7, 2020, 152, https: / / doi.org / 10.1038 / s41438-020-00390-1.

Claims

Attorney Docket No.: 690104.0045We claim;1. A bioluminescent organism comprising a bioluminescent transgene cassette, wherein said bioluminescent organism expresses a plurality of heterologous genes of a bioluminescence pathway,wherein two or more of the genes of a bioluminescence pathway are included in a bioluminescent transgene cassette,wherein the genes in the bioluminescent transgene cassette are transcribed as a single transcript, andwherein the single transcript is translated into a separate protein for each gene within the cassette.

2. The bioluminescent organism of claim 1,wherein the genes of the bioluminescence pathway comprise HispS, H3H, LUZ, CPH, and npgA;wherein the bioluminescent transgene cassette comprises three or more, preferably four or more, and most preferably all five of the genes of the bioluminescence pathway;wherein two, three, or four of the bioluminescence pathway genes are on the bioluminescent transgene cassette and the remaining bioluminescence pathway genes are external to the cassette, optionally wherein two or three of the remaining bioluminescence pathway genes are part of a second bioluminescent transgene cassette that are transcribed as a single transcript;wherein the genes in the bioluminescent transgene cassette are separated from one another by one or more linkers that are self-cleaving linkers or protein cleavage sites, optionally wherein the linker comprises LP4, 2A, GSG, or combinations thereof, optionally wherein the linker comprises one or more of SEQ ID NOs: 78-79, 81-82, 84-85, 87-88, 91-92, 94-95, 97-98, 100-101, 104-105, 107-108, 110-111, 113-114, 117-118, 120-121, 123-124, 126-127, 130-131, 133-134, 136-137, 139-140, 143-144, 146-147, 149-150, 152-153, 156-157, 159-160, 162-163, 165-166, 169-170, 172-173, 175-176, 178-179, 182-183, 185-186, 188-189, 191-192, 195-196, 198-199, 201-202, 204-205, 208-209, 211-212, 214-215, 217-218, 221-222, 224-225, 227-228, and 230-231;Attorney Docket No.: 690104.0045wherein the bioluminescent transgene cassette comprises a nucleotide sequence selected from SEQ ID NOs: 1-12 or 233-236;wherein the bioluminescent organism is a plant or an animal;wherein one or more of the genes of the bioluminescent pathway have been modified from the wild type by one or more of: removal of intron splice sites, codon optimization, and altering GC content, optionally wherein GC content is increased to 50% or more, 52% or more, 54% or more, 56% or more, 58% or more, or 60% or more;wherein one or more of the genes of the bioluminescence pathway comprise a nucleotide sequence selected from the group consisting of SEQ ID NOs: 77, 80, 83, 86, 89-90, 93, 96, 99, 102-103, 106, 109, 112, 115-116, 119, 122, 125, 128-129, 132, 135, 138, 141-142, 145, 148, 151, 154-155, 158, 161, 164, 167-168, 171, 174, 177, 180-181, 184, 187, 190, 193-194, 197, 200, 203, 206-207, 210, 213, 216, 219-220, 223, 226, 229, and 242-246;wherein one or more of the genes of the bioluminescence pathway comprise a variant gene of HispS, H3H, LUZ, CPH, and npgA such that the nucleotide sequence, when translated, produces a variant protein with an amino acid sequence that differs from the wildtype amino acid sequence;wherein the variant gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 13-76; and / orwherein the variant protein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 247-278.

3. The bioluminescent organism of claim 1 or claim 2, wherein the one or more of the genes of the bioluminescent pathway are linked to each other by one or more LP4 / 2A ribosomal skipping peptides.

4. The bioluminescent organism of any one of claims 1-3, wherein the one or more of the genes of the bioluminescent pathway are codon-optimized.

5. The bioluminescent organism of any one of claims 1-4, wherein the one or more of the genes of the bioluminescent pathway lack predicted intron donor sites and predicted intron acceptor sites.Attorney Docket No.: 690104.00456. The bioluminescent organism of any one of claims 1-5, wherein the one or more of the genes of the bioluminescent pathway have a GC content between 50% and 70%.

7. The bioluminescent organism of any one of claims 1-6, wherein the one or more of the genes of the bioluminescent pathway are transcribed into a single 9.5 kb transcript.

8. The bioluminescent organism of any one of claims 1-7, wherein the one or more of the genes of the bioluminescent pathway comprise HispS, H3H, CPH, and npgA.

9. The bioluminescent organism of any one of claims 1-8, wherein the single transcript comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, and SEQ ID NO: 236.

10. The bioluminescent organism of any one of claims 1-9, wherein the single transcript encodes a variant protein comprising an amino acid sequence of any one of SEQ ID NOs: 247-278.

11. The bioluminescent organism of any one of claims 1-10, wherein the variant protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 263, SEQ ID NO: 266, SEQ ID NO: 269, SEQ ID NO: 275, and SEQ ID NO: 276.

12. The bioluminescent organism of any one of claims 1-11, wherein the variant protein comprises the mutations A43T, T66I, S102P, and D263Arelative to an H3H polypeptide of SEQ ID NO: 239.

13. The bioluminescent organism of any one of claims 1-12, wherein the variant protein increases the bioluminescence of the bioluminescent organism by at least 16-folds.

14. The bioluminescent organism of any one of claims 1-13, wherein the bioluminescent organism expresses a variant protein comprising SEQ ID NO: 269.Attorney Docket No.: 690104.004515. The bioluminescent organism of any one of claims 1-14, wherein the bioluminescent organism is an animal.

16. The bioluminescent organism of any one of claims 1-1, wherein the animal is a fish, an arthropod, or a mammal.

17. The bioluminescent organism of any one of claims 1-14, wherein the bioluminescent organism is a plant.

18. The bioluminescent organism of claim 17, wherein the plant is an ornamental plant.

19. The bioluminescent organism of any one of claims 1-18, wherein the ornamental plant is a petunia, impatiens, rose, begonia, geranium, or the like.

20. A bioluminescent transgene cassette, wherein said bioluminescent transgene cassette comprises two or more genes of a bioluminescence pathway,wherein the genes in the bioluminescent transgene cassette are transcribed as a single transcript, andwherein the single transcript is translated into a separate protein for each gene within the cassette.

21. The bioluminescent transgene cassette of claim 20,wherein the genes of the bioluminescence pathway comprise one or more genes selected from the group consisting of HispS, H3H, LUZ, CPH, and npgA;wherein the bioluminescent transgene cassette comprises three or more, preferably four or more, most preferably all five of the genes of the bioluminescence pathway;wherein two, three, or four of the bioluminescence pathway genes are on the bioluminescent transgene cassette and the remaining bioluminescence pathway genes are external to the cassette, optionally wherein two or three of the remaining bioluminescenceAttorney Docket No.: 690104.0045pathway genes are part of a second bioluminescent transgene cassette that are transcribed as a single transcript;wherein the genes in the bioluminescent transgene cassette are separated from one another by one or more linkers that are self-cleaving linkers or protein cleavage sites, optionally wherein the linker comprises LP4, 2A, GSG, or combinations thereof, optionally wherein the linker comprises one or more of SEQ ID NOs: 78-79, 81-82, 84-85, 87-88, 91-92, 94-95, 97-98, 100-101, 104-105, 107-108, 110-111, 113-114, 117-118, 120-121, 123-124, 126-127, 130-131,133-134, 136-137, 139-140, 143-144, 146-147, 149-150, 152-153, 156-157, 159-160, 162-163,165-166, 169-170, 172-173, 175-176, 178-179, 182-183, 185-186, 188-189, 191-192, 195-196,198-199, 201-202, 204-205, 208-209, 211-212, 214-215, 217-218, 221-222, 224-225, 227-228, and 230-231;wherein the bioluminescent transgene cassette comprises a nucleotide sequence selected from SEQ ID NOs: 1-12 or 233-236;wherein one or more of the genes of the bioluminescent pathway have been modified from the wild type by one or more of: removal of intron splice sites, codon optimization, and altering GC content, optionally wherein GC content is increased to 50% or more, 52% or more, 54% or more, 56% or more, 58% or more, or 60% or more;wherein one or more of the genes of the bioluminescence pathway comprise a nucleotide sequence selected from the group consisting of SEQ ID NOs: 77, 80, 83, 86, 89-90, 93, 96, 99,102-103, 106, 109, 112, 115-116, 119, 122, 125, 128-129, 132, 135, 138, 141-142, 145, 148, 151,154-155, 158, 161, 164, 167-168, 171, 174, 177, 180-181, 184, 187, 190, 193-194, 197, 200,203, 206-207, 210, 213, 216, 219-220, 223, 226, 229, and 242-246;wherein one or more of the genes of the bioluminescence pathway comprise a variant gene of HispS, H3H, LUZ, CPH, and npgA such that the nucleotide sequence, when translated, produces a variant protein with an amino acid sequence that differs from the wildtype amino acid sequence; and / or.wherein the variant gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 13-76; and / orwherein the variant protein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 247-278.Attorney Docket No.: 690104.004522. The bioluminescent transgene cassette of claim 20 or claim 21, wherein the one or more of the genes of the bioluminescent pathway are linked to each other by one or more LP4 / 2A ribosomal skipping peptides.

23. The bioluminescent transgene cassette of any one of claims 20-22, wherein the one or more of the genes of the bioluminescent pathway are codon-optimized.

24. The bioluminescent transgene cassette of any one of claims 20-23, wherein the one or more of the genes of the bioluminescent pathway lack predicted intron donor sites and predicted intron acceptor sites.

25. The bioluminescent transgene cassette of any one of claims 20-24, wherein the one or more of the genes of the bioluminescent pathway have a GC content between 50% and 70%.

26. The bioluminescent transgene cassette of any one of claims 20-25, wherein the one or more of the genes of the bioluminescent pathway are transcribed into a single 9.5 kb transcript.

27. The bioluminescent transgene cassette of any one of claims 20-26, wherein the one or more of the genes of the bioluminescent pathway comprise HispS, H3H, CPH, and npgA.

28. The bioluminescent transgene cassette of any one of claims 20-27, wherein the single transcript comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, and SEQ ID NO: 236.

29. The bioluminescent transgene cassette of any one of claims 20-28, wherein the single transcript encodes a variant protein comprising an amino acid sequence of any one of SEQ ID NOs: 247-278.

30. The bioluminescent transgene cassette of any one of claims 20-29, wherein the variant protein is selected from the group consisting of SEQ ID NO: 263, SEQ ID NO: 266, SEQ ID NO: 269, SEQ ID NO: 275, and SEQ ID NO: 276.Attorney Docket No.: 690104.004531. The bioluminescent transgene cassette of any one of claims 20-30, wherein the variant protein comprises the mutations A43T, T66I, S102P, and D263A relative to an H3H polypeptide of SEQ ID NO: 239.

32. The bioluminescent transgene cassette of any one of claims 20-31, wherein the variant protein increases bioluminescence by at least 16-folds.

33. The bioluminescent transgene cassette of any one of claims 20-32, wherein the variant protein comprises SEQ ID NO: 269.

34. A method of producing a bioluminescent organism comprising transforming a cell with the bioluminescent transgene cassette of any one of claims 20-33, and culturing the cell to producing an organism that expresses the variant protein, wherein the bioluminescent organism is a plant or animal.

35. The method of claim 34, wherein the bioluminescent organism is an animal.

36. The method of claim 34 or 35, wherein the animal is a fish, an arthropod, or a mammal.

37. The method of claim 34, wherein the bioluminescent organism is a plant, and wherein the method comprises regenerating a transgenic plant from a plant cell.

38. The method of claim 37, wherein the plant is an ornamental plant.

39. The method of claim 38, wherein the ornamental plant is a petunia, impatiens, rose, begonia, geranium, or the like.

40. A variant bioluminescence pathway protein comprising an amino acid sequence of any one of SEQ ID NOs: 247-278.Attorney Docket No.: 690104.004541. The variant bioluminescence pathway protein of claim 40, wherein the variant protein is selected from the group consisting of SEQ ID NO: 263, SEQ ID NO: 266, SEQ ID NO: 269, SEQ ID NO: 275, and SEQ ID NO: 276.

42. The variant bioluminescence pathway protein of claim 40 or claim 41, wherein the variant protein comprises the mutations A43T, T66I, S102P, and D263A relative to an H3H polypeptide of SEQ ID NO: 239.

43. The variant bioluminescence pathway protein of any one of claims 40-42, wherein the variant protein increases bioluminescence by at least 16-folds.

44. The variant bioluminescence pathway protein of any one of claims 40-43, wherein the variant protein comprises SEQ ID NO: 269.

45. A mutant H3H polypeptide exhibiting enhanced bioluminescence activity relative to a H3H polypeptide of SEQ ID NO: 239, comprising one or more amino acid substitutions selected from the group consisting of A43T, S58C, Q60L, T66I, G81A, S102P, M116R, V118L, T138V, F139S, V147I, V161I, E176G, V187A, T220A, R233H, A251G, N260D, A262V, D263A, A268V, S269T, R285K, Q292D, M323S, D367E, and S408A.

46. A mutant H3H polypeptide exhibiting enhanced bioluminescence activity relative to a H3H polypeptide of SEQ ID NO: 239, comprising one or more amino acid substitutions selected from the group consisting of A43T, S58C, Q60L, Q61G, T66I, G71P, A79R, S102P, M116R, T138V, V147I, V161I, E176G, K210N, T220A, N260D, D263A, S265N, A268V, K270Q, R285K, M323S, and E379Q.

47. A mutant H3H polypeptide exhibiting enhanced bioluminescence activity relative to a H3H polypeptide of SEQ ID NO: 239, comprising one or more amino acid substitutions selected from the group consisting of A43T, S58C, Q60L, T66I, G71P, G81A, S102P, F139S, V161I, E176G, V187A, K210N, T220A, A251G, T261S, D263A, S265N, S269T, K270Q, R285K, M323S, D367E, and L395M.Attorney Docket No.: 690104.004548. A mutant H3H polypeptide exhibiting enhanced bioluminescence activity relative to a H3H polypeptide of SEQ ID NO: 239, comprising one or more amino acid substitutions selected from the group consisting of A43T, S58C, Q60L, Q61G, G71P, A79R, S102P, M116R, V118L, F139S, V147I, V161I, E176G, V187A, K210N, A251G, A262V, D263A, R285K, Q292D, M323S, E379Q, L395M, and S408A.

49. A mutant H3H polypeptide exhibiting enhanced bioluminescence activity relative to a H3H polypeptide of SEQ ID NO: 239, comprising one or more amino acid substitutions selected from the group consisting of A43T, Q61G, T66I, G71P, S102P, M116R, F139S, V147I, V161I, E176G, V187A, K210N, R233H, A251G, N260D, T261S, D263A, S265N, A268V, S269T, Q292D, D367E, E379Q, and S408A.

50. A variant bioluminescence pathway gene comprising a nucleotide sequence of any one of SEQ ID NOs: 77, 80, 83, 86, 89-90, 93, 96, 99, 102-103, 106, 109, 112, 115-116, 119, 122, 125, 128-129, 132, 135, 138, 141-142, 145, 148, 151, 154-155, 158, 161, 164, 167-168, 171, 174, 177, 180-181, 184, 187, 190, 193-194, 197, 200, 203, 206-207, 210, 213, 216, 219-220, 223, 226, 229, 242-246, and 13-76.

51. A recombinant expression vector comprising the variant bioluminescence pathway gene of claim 50.

52. A host cell comprising the recombinant expression vector of claim 51.

53. The host cell of claim 52, wherein the host cell is an animal cell.

54. The host cell of claim 52, wherein the host cell is a plant cell.

55. A transgenic animal comprising the host cell of claim 53.

57. A transgenic plant comprising the host cell of claim 54.